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ABSTRACT 
Van Wallace McCarlie, Jr. 
 
THE IMMUNOGENETICS OF DENTAL CARIES 
Background: Bacterial adherence to the acquired dental pellicle, important 
in caries, is mediated by receptor-adhesin interactions such as Streptococcus 
mutans antigen I/II (I/II). Ten I/II epitopes from the A, V, P and C regions were 
chosen to determine their reactivity in human saliva. Underlying the body’s 
ability to immunologically respond to bacteria that lead to caries are the human 
leukocyte antigen (HLA) genes, specifically HLA class II (HLA-II) genes that 
control antigen presentation. Previous studies suggested that a specific HLA 
biomarker group (HLA-DRB1*04) may have differential control of immune 
responses to I/II. However, it was not known whether secretory IgA (SIgA) 
responses to the selected epitopes from HLA-DRB1*04 positive subjects were 
different compared to their non-biomarker counterparts (negative), or across 
other caries factors, since no study to date had thus assessed these questions. 
Methods: Per IRB approval, the study population was divided into age, 
sex and race matched DRB1*04 positive (n=16) and negative groups (n=16). SIgA-
epitope (and whole cell) reactivity was determined using ELISA. Other caries 
factors were measured. Subjects received a clinical exam by a trained examiner. 
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Differences between DRB1*04 positive and negative groups were examined 
using a two-sided, two-sample t-test. 
Results: DRB1*04 positive subjects had numerically, but not statistically, 
higher reactivity to 9 out of 10 epitopes, the exception being residues 834-853 
from the V and P regions of I/II across multiple measures. Though statistically 
insignificant, DRB1*04 positive subjects also exhibited 25-30 µg mL-1 less total 
IgA (TIgA) than negative counterparts. All clinical caries data proved 
inconclusive when comparing groups, likely due to exogenous factors and 
sample size.  
Conclusion: DRB1*04 positive subjects showed a trend toward lower 
TIgA. Moreover, they also showed a lower SIgA response across multiple 
measures to 834-853, the I/II V and P region epitope. This region forms a sort of 
functional epicenter involved in collaboration between domains along the entire 
I/II antigen, and governs the region involved in initial attachment to the acquired 
dental pellicle. This region may be involved in an in vivo discontinuous 
conformationally specific immunogenic epitope that serves as an HLA-II binding 
motif which remains elusive. 
           Richard L. Gregory, PhD, Chair 
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CHAPTER ONE 
 
Dental Caries and Human Genetics 
Dental caries (caries) is a multifactorial oral disease that ubiquitously, 
albeit unevenly, affects the world population. Caries often produces severe 
“consequences of pain and dysfunction,” which interfere with the “most basic 
functions of eating, sleeping, speaking, being productive and enjoying general 
health” (Edelstein, 2006). Although caries has been thought to be a 
predominantly environmentally-related disease, the full range of this infectious 
disease cannot be explained by environmental variables. Four major factors 
which directly contribute to caries development include the host, bacteria in the 
oral biofilm, diet (quality, quantity, and frequency), and time (Harris et al., 2009; 
Pinkham, 2005; Selwitz et al., 2007). Except for time, all of these factors are 
modified by host genes. Tooth anatomy and morphology as well as dentin and 
enamel mineralization, for example, are genetically controlled (Haruyama et al., 
2009; Stephanopoulos et al., 2005; Townsend et al., 2003). In animal and human 
studies, differences in genetic background produce divergent 
immunomodulatory effects against bacterial antigens involved in caries 
(Robinette et al., 2009; Wallengren et al., 2005). Recent genetic evidence also 
points to the interesting fact that the types and levels of oral bacteria colonized in 
humans (i.e., the human oral microbiome) are genetically regulated by the host 
(Corby et al., 2007; Corby et al., 2005). Though the host and the oral microbiome 
are genetically modulated, so too is the diet.  
Research has demonstrated that the proverbial sweet tooth is not as far-
fetched as initially thought, and that a nuanced view reveals genetic background 
significant to sucrose sweetness preference (Bretz et al., 2006; Fushan et al., 2009). 
We now understand that a variety of behaviors are under significant genomic 
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control such as our sleep patterns or when we do things during the day (Brown 
et al., 2008), which would include eating and snacking. Oral hygiene would be 
included in this framework as it is predominatly a behavioral phenomenon, and 
as such, its genetic regulation cannot be underestimated. One study that has 
important implications for oral hygiene was done in the context of social reward 
(Caldu and Dreher, 2007). Those who had a particular variant of a reward gene 
were much more likely to accomplish a novel task, for our purposes brushing 
correctly, in the face of a social reward. Alternatively, those who had a different 
reward gene variant were much more likely to lack motivation altogether to 
complete the task at hand (e.g., brushing). What have traditionally been 
considered purely environmental and personal variables are, therefore, also 
genetically regulated.  
Thus, the caries process is under more genetic control than is provided for 
in the traditional caries paradigm. However, it is very important to understand 
that when we say caries is genetically regulated, we are not saying that genetics 
explains 100 percent of the disease. In other words, caries is a multifactorial 
disease because it has a significant environmental component, there are multiple 
genes involved, there are gene-environment interactions at play, and the risk 
runs in families in a non-Mendelian manner. This simply means that the disease 
process “arises from the complex interaction of environmental and host genetic 
factors” (Burgner et al., 2006). The epigenetics of caries has not been discussed, 
but provides almost an infinite number of possibilities since the heritable 
changes that are passed on control how genes (e.g., associated with caries) are 
expressed, and therefore how proteins downstream function (Rodenhiser and 
Mann, 2006). It is important to understand that environmental insults interacting 
with host genes can produce “epigenetic patterns and thereby effect changes in 
gene activation and cell phenotype” (Barros and Offenbacher, 2009) over 
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generations. It would make sense, then, that genes and environment are 
inextricably tied to each other. Epigenetics, therefore, should provide the nexus 
for a new frontier which bridges the gap between genetics, oral disease, and 
environmental variables. This multifactorial nature of caries should not surprise 
us since the preponderance of evidence in both animal and human models 
demonstrate that caries susceptibility has a significant genetic component and 
that multiple genes are at work (Boraas et al., 1988; Conry et al., 1993; Finn and 
Caldwell, 1963; Horowitz et al., 1958; Hunt et al., 1944; Jackson et al., 1973).  
The genomic puzzle of caries is just beginning to be unraveled, however, 
and the pieces are just beginning to be put in place. Researchers have now 
published the first genome-wide scan for caries, which demonstrated that 
chromosome 6 housing the Human Leukocyte Antigen (HLA) complex was 
among 5 chromosomes revealing unique and significant results with regards to 
caries susceptibility in a non-parametric linkage analysis (Vieira et al., 2008). This 
research attempts to focus on one piece of the genomic puzzle—HLA class II 
genes and the caries process.     
The link between HLA Class II Genes and the Caries Process 
Almost a half century ago it was discovered that HLA genes play a major 
role in modulating immunity. Interchangeably called the human major 
histocompatibility complex (MHC) or HLA (Shiina et al., 2009), this region is one 
of the most vital genomic areas with regard to infectious disease (Horton et al., 
2004). A link has been suggested between HLA class II (HLA-II) alleles and this 
region because the molecules encoded by these alleles are inextricably tied to 
inducing how humans fight against bacterial threats (by presenting antigen 
efficiently, inefficiently or not at all).  
The connection between HLA-II alleles—via HLA-encoded proteins and 
bacterial antigens—and caries has become an area of tremendous possibility. One 
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of the chief causative bacterial pathogens in caries is a member of the mutans 
streptococci family, Streptococcus mutans (Loesche, 1986; Mitchell, 2003), whose 
immunopathogenesis has been associated with specific HLA-II alleles. Similarly, 
recent studies suggest that other members of the streptococcal family, including 
Streptococcus pneumonia (Boyton et al., 2008) and Streptococcus pyogenes (Kotb et 
al., 2002), are also immunopathogenically associated with specific HLA-II alleles. 
Current studies have found associations between other infectious bacteria (e.g., 
Mycobacterium leprae), the diseases they cause, and specific HLA-II alleles 
(Vanderborght et al., 2007).  
In the case of caries, it is unclear if there are significant associations 
between specific HLA-II alleles and the disease itself, although the HLA-II 
association is clearer with regard to the organisms implicated in the caries 
process, including and especially mutans streptococci. Nontheless, the 
preponderance of evidence suggests that there is a significant association 
between specific HLA-II alleles and caries. The common denominator across all 
caries factors are bacteria (i.e., the cariogenic agent), which colonize the human 
oral microbiome and attach themselves to the tooth structure. If we take bacteria 
out of the equation, caries does not develop (Casanova and Abel, 2004), as was 
shown more than 5 decades ago using gnotobiotic rats (Orland et al., 1954). How 
the host deals with cariogenic bacteria is one of the most important questions in 
understanding how the biological system produces resistant or susceptible 
disease outcomes, including caries. Focusing on HLA-II alleles makes sense 
because their proteins are responsible for presenting antigen to T cells in mucosal 
immunity, ultimately (assuming no immunogenetic dysfunction) providing 
appropriate mucosal immunity against bacterial cariogens such as mutans 
streptococci. By doing so, we may unravel some of the complex relationships 
between host HLA genomics, immunity, and the infectious disease of caries.  
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HLA Genetics and Caries 
 Researchers have suggested significant and important associations 
between HLA-II genes, HLA-II proteins and Antigen I/II (I/II), which is found on 
the cell surface of most strains of S. mutans and several other species that are 
potentially cariogenic (Tsuha et al., 2004). Antigen I/II is an immunodominant 
antigen of S. mutans with respect to activating antibody responses. Although a 
variety of researchers have termed I/II differently, including P1, the term I/II will 
be used throughout this dissertation. This surface adhesin allows bacteria to 
attach to salivary agglutinin (SAG) found in the layer of salivary glycoproteins 
deposited on teeth called the dental pellicle, which then forms dental plaque (or 
biofilm). While it is becoming increasingly clear that other bacterial species 
should be explored when considering caries, “no other species is yet a serious 
contender to S. mutans for a role as a worthwhile marker organism” for caries 
(Russell, 2008). Thus, S. mutans has been, and continues to be, the model 
organism for caries research. Those interested in the effect of HLA-II genes and 
their proteins on caries have thus used it (and its associated antigens) as the 
pathogenic model in animals and humans. 
 Animal and human studies suggest that HLA-II genes play a role in the 
development of caries. Rat Major Histocompatability Complex (MHC) genes 
clearly regulate immunity against S. mutans (Niiyama et al., 1987). One set of 
researchers showed that murine MHC genes, found in the H-2 region, controlled 
serum IgG response to I/II A-region epitopes (Takahashi et al., 1992). The murine 
H-2 region, corresponding to the HLA region in humans, has also a marked 
effect on clinical caries (measured by the modified Keyes method) susceptibility 
(Suzuki and Kurihara, 1998). Thus, animal and human studies suggest that these 
genes control immunity against the bacteria, and more specifically its associated 
antigens that are, in large measure, responsible for the caries process.  
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A foundational paper by Lehner et al. in England, involving human 
subjects, suggested an immune gene effect on caries by demonstrating that 10 
patients who expressed HLA-DR4 (i.e., HLA-DRB1*04) antigens tended to be 
caries susceptible and failed to mount an immune response to I/II, measured by 
T-cell helper function via an antibody-forming cell assay, until the concentration 
of I/II was increased 1000 times (Lehner et al., 1981). The other 14 subjects who 
were typed as DR1, DR2, DR3, and DRw6 [i.e., DRB1*01, DRB1*02, DRB1*03, and 
DRB1*13 or 14 (Burmester et al., 2003)] were caries resistant and mounted 
immune responses to low doses of I/II. These results were statistically and 
dramatically significant, and the evidence demonstrated a link between a 
common clinical measure of caries, DMFS (decayed, missing due to caries, and 
filled tooth surfaces), and HLA-DR4-gene products. Another study found that 
DR4 patients exhibited more than double the suppressive regulatory T cell (Treg) 
activity than their DRw6 counterparts at a low concentration of I/II, further 
suggesting that DR4 subjects, under certain conditions, respond differently to a 
specific S. mutans antigen (Lehner, 1982).  
One set of Swedish researchers has therefore tested the purported 
hypothesis (Lehner, 1982) that those patients who are DR4 positive are more 
likely to have higher levels of oral mutans streptococci. This group has found on 
two separate occasions a trend that supports this hypothesis. One study of 76 
renal transplant patients demonstrated that all DR4 positive patients exhibited 
high levels of mutans streptococci, whereas those who were DR4 negative were 
more likely to have statistically significantly lower levels of mutans streptococci 
(Wallengren et al., 1991). The same study demonstrated a similar trend in healthy 
subjects although it did not reach statistical significance. This same trend in 
healthy subjects was also observed in a follow-up study, and a side note 
mentioned by the authors is that one participant, who was homozygous for DR4, 
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exhibited the highest levels of mutans streptococci correlating with a very high 
DMFS index (Wallengren et al., 1997), DMFS being an indicator of the extent of 
caries in a subject.  
 Although previous studies suggested a DR4-caries connection, none of 
these studies provided high resolution genotyping as the antigens tested were 
determined by immunological reactions and not direct DNA sequencing. 
Knowledge of HLA genetics changes and advances by the day, and 
methodologies and understandings have dramatically advanced and changed 
since these studies were done.  
 The first set of researchers, led by Acton, to use an updated nomenclature 
in testing various HLA-II alleles against levels of S. mutans and caries (measured 
by DMFS) indicated that African-American women demonstrated similar trends 
(up to this point only Caucasian populations had been studied), but the 
association to caries did not reach statistical significance (Acton et al., 1999). 
However, there were associations between HLA-DRB1*04 and *03 alleles and 
high levels of S. mutans (depending on the inclusion criteria). Of interest is that 
when the authors excluded those who had no signs of clinical disease, they 
found that the DRB1*04 association with bacterial counts gained tremendous 
statistical strength (Odds Ratio = 11.8, 95% CI = 2.09-66.2, p = 0.005), although the 
*03 association lost significance altogether. This supports the complex nature of 
this disease process, where host factors may interact with bacterial factors to 
increase the susceptibility of the host, although the actual pathological process is 
likely to be influenced by other factors as well.   
In another non-Caucasian Asian cohort, a variety of alleles from three loci, 
including HLA-DQA1, DQB1, and DRB1, as well as a variety of haplotypes, were 
examined (Ozawa et al., 2001). The authors found that the DRB1*04 association 
with mutans streptococci was not significant and hypothesized that the 
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difference might be explained by population or ethnic differences. This is a 
distinct possibility. One set of authors recently observed that it is extraordinary, 
but nonetheless a fact that identical diseases, such as an autoimmune disease, 
may be associated with different HLA-II alleles “in different ethnic or racial 
populations” (Bondinas et al., 2007). The researchers examining an Asian 
population did find that mutans streptococci levels were weakly associated with 
a different allele, specifically HLA-DQB1*0601. Even so, the authors admitted 
that if they had a larger sample size they might have been able find more robust 
associations between important HLA-II alleles and oral microorganisms. This is a 
common limitation when examining a specific HLA-II allelic variant and its 
association with disease. For instance, of the total sample size of 106 in their 
study, only 3 subjects were DRB1*0401 positive, whereas they had approximately 
30 subjects who were positive for DQB1*0601, the variant they found to be 
weakly associated with mutans streptococci. These limitations have typically led 
to observable trends not reaching statistical significance. 
Another study in a Caucasian sample demonstrated that a particular 
allelic variant of DRB1*04, *0401, was found to be statistically associated with 
salivary IgA activity, those who were DRB1*04 positive were significantly 
different from those who were *04 negative (Wallengren et al., 2001). As is well 
known, antibodies play a major role in immunity and are linked to HLA 
genetics. The predominant secretory antibody in saliva is secretory IgA (SIgA), 
with the IgA:IgG ratio in oral secretions from the parotid gland being 500 times 
greater than that of serum (Brandtzaeg, 2007). In the protease-laden environment 
of the oral cavity, SIgA is remarkably stable, and active against S. mutans. A 
majority of the evidence indicates that a higher level of salivary IgA in the oral 
cavity is related to a lower level of caries (Gregory et al., 1990). In a 2005 follow-
up study, with a much larger sample size (n=58 DRB1*04 positive; in contrast to 
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n=19), these results were confirmed. For example, those subjects who exhibited 
immunodeficiency—as recently conceptualized (Casanova and Abel, 2004)—
against whole cell extracts of S. mutans and S. sobrinus, and I/II, were all DRB1*04 
positive. These data demonstrated that they were either entirely unable to mount 
a detectable IgA response or their response was significantly lower than DRB1*04 
negative subjects (Wallengren et al., 2005). Of the DRB1*04 allelic variants 
analyzed, only DRB1*0401 was found to reach statistical significance although it 
is clear from the raw data that it cannot be concluded that the other allelic 
variants did not lead to the same outcome (after analyzing *0401, *0404, *0402, 
*0403, *0405, *0407, *0408, *0414, and *04 negative persons). Virtually everyone 
that did not mount IgA responses against S. mutans were DRB1*04 positive. Of 3 
human samples that demonstrated no detectable immune response against I/II, 
all were DRB1*0401.  
In an Iranian cohort of children published very recently, HLA-DRB1*04 
positive children were 10 times more likely to have early childhood caries (ECC) 
(Bagherian et al., 2008). This is interesting from the standpoint that all 79 subjects 
were between the ages of 12 and 72 months, which has significance with regard 
to both the natural history of caries and the development of the salivary immune 
response. Although colonized with certain types of oral streptococci (i.e., 
Streptococcus salivarius and Streptococcus mitis) as newborns, children are likely 
not permanently infected with mutans streptococci, meaning predominantly S. 
mutans and S. sobrinus, which are the main cariogenic agents in caries, until 
anywhere from 18 to 36 months (Taubman and Nash, 2006). Permanent infection 
with some of the mutans group does not happen until tooth eruption begins, 
instead of only the 18-36 month range, although we now know this can happen 
earlier, but colonizing numbers are lower and harder to detect until the primary 
molars start erupting. Newborns lack significant levels of SIgA, but by 12 to 24 
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months most children have SIgA levels similar to those found in adults. 
Unfortunately, the Iranian study did not analyze levels of mutans streptococci 
colonization or SIgA. The significance in knowing whether someone has an 
HLA-II susceptibility allele for caries is apparent if HLA-II-mediated 
immunodeficiency or immune dysfunction with regard to IgA immunity leads to 
the initial colonization of mutans streptococci, and the development of caries. Of 
35 children who did not have ECC, 34 of them, or 97 percent, were DRB1*04 
negative.  
The preponderance of the evidence, albeit uneven, suggests an association 
between specific HLA-II alleles, especially DRB1*04 in Caucasians, and caries. 
That said, human studies conducted heretofore have had limitations that must be 
remedied, especially with regard to sample size and allele frequency. This 
purported association needs further validation studies to advance the science of 
HLA genetics and caries. Furthermore, the HLA-II association and its ultimate 
significance with regard to understanding caries are certainly not one-to-one. A 
specific HLA-II allele, or some combination of them, will surely not explain all of 
the variation seen in caries. To underscore an earlier point, caries is a complex 
disease, and as such, develops amidst multiple genetic and environmental 
factors. Amidst the genetic puzzle, this research only focuses on one of the 
genetic pieces, albeit potentially more important than we now understand. By 
understanding how particular HLA-II alleles make one susceptible or resistant to 
the clinical infectious disease of caries, we will unravel part of the genetic puzzle. 
Our lack of detailed understanding with regard to how HLA-II alleles make one 
susceptible or resistant to caries is a general problem that has yet to be solved across 
a spectrum of diseases. This problem will not be solved anytime soon, but the 
more we know the closer we are. 
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A Functional Immunogenetic Framework: Mechanisms connecting HLA-II to 
Caries  
The mechanisms involved in how specific HLA-II alleles may make one 
susceptible to caries are essentially unknown or unproven. Although the general 
points of connection between genes and immunity are fairly clear, the details 
remain murky. As is well known, antibodies play a major role in immunity and 
are linked to HLA genetics. From the immunity standpoint, a majority of the 
evidence indicates that a higher level of salivary IgA antibodies against S. mutans 
antigens in the oral cavity is related to a lower level of caries (Brandtzaeg, 2007). 
High salivary IgA antibody levels relate to low levels of S. mutans during early 
oral colonization, and low levels of salivary IgA correlate with high levels of S. 
mutans and caries experience (Nogueira et al., 2005). The working hypothesis of 
how this happens is that salivary IgA interacts with critical epitopes of adhesins 
of cariogenic bacteria (i.e., I/II, GTFs [glucosyltransferases], or GBPs [glucan-
binding proteins]), blocking these adhesins and thus inhibiting their function, or 
alternatively, priming S. mutans to become opsonized, phagocytosed, and 
destroyed by gingival neutrophils, thus depriving S. mutans (or similar 
cariogenic bacteria) of its ability to attach to the tooth surface and produce 
disease. Any type of immunity against caries must inhibit bacterial adhesion or 
facilitate clearance of mutans streptococci (via aggregation), thus preventing 
lesion formation (Fontana et al., 2000). An immunodeficiency or some level of 
immune dysfunction with regard to cariogenic bacteria (e.g., lack of, or low 
levels of IgA) will lead to caries.  
There are seemingly 3 major putative ways that immunodeficiency may 
occur in relation to caries. First, SIgA antibody response to cariogenic bacteria 
may be, under specific biological conditions, greatly suppressed by Tregs. It has 
been suggested that pathogen survival and persistence may be a homeostatic 
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compromise on the heels of excessive Treg regulation (Belkaid and Rouse, 2005). 
In an earlier study, when little was known about Tregs, DR4 patients exhibited 
more than double the suppressive regulatory T cell (Treg) activity than their 
DRw6 counterparts at a low concentration of I/II, further suggesting that DR4 
subjects, under certain conditions, respond differently to a specific S. mutans 
antigen (Lehner, 1982). This is certainly a possibility, and a similar mechanism 
has been shown to occur in the immune response to herpes simplex virus (HSV), 
hepatitis C virus, and HIV (Belkaid and Rouse, 2005). Mice that have been 
depleted of their Treg repertoire have demonstrated increased immunity to HSV. 
This phenomenon occurs across a spectrum of immune responses including 
CD4+ and CD8+ T cell activity, “as well as mucosal antibody concentration.” 
Thus, Tregs might see specific bacterial peptides bound to DRB1*0401-encoded 
molecules (or other specific *04 allelic variants) and suppress host immune 
responses against cariogenic bacteria, producing deleterious levels of bacteria 
within the oral cavity. Some Tregs are not peptide specific but instead see class II 
molecules generally. How this would regulate caries response is less clear. Of 
note is that there is also evidence that Tregs can regulate the secondary responses 
to infections such as listeria, HSV or leishmania. How this occurs remains 
ambiguous.     
Second, HLA-II alleles (i.e., DR, DP & DQ or their variants) may compete 
for disease related peptides, thus the DRB1*0401 (or other)-encoded protein 
variant might bind a peptide, albeit inefficiently, that in the context of another 
class II molecule (DP or DQ) might drive an efficient and robust immune 
response. It is becoming clearer that both HLA-I and -II allelic variants provide 
significantly different biological responses. For example, T-cell mediated 
immunity increases by 10-fold against an Epstein-Barr virus epitope when a 
particular HLA-I allelic variant, differing by only one amino acid from other 
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related alleles, is present (Archbold et al., 2009). In this case, the outcome is 
beneficial. Early on it was shown that HLA restriction was important with regard 
to cariogenic bacteria. Thus, the capture of bacterial epitopes by specific class II 
alleles may promote or thwart protective immunity.  
Third, the DRB1*04 allelic variant peptide complex might activate a 
distinct type of CD4 T cells, such as interleukin-17 (IL-17) producing cells, which 
promote inflammation but not necessarily beneficial bacterial clearance or 
antibody responses. These cells work within what has been called the Th17 
pathway (Steinman, 2007), which ties us back to our first mechanistic idea of 
Tregs, as Th17 cells can modulate Tregs and produce inflammatory IL-17. Th17 
cells can produce sustained tissue damage (in brain, heart, joint, lung, bone, and 
intestinal models) leading to autoimmunity, while antagonizing Th1 cells, which 
have now been shown under the revised Th1/Th2 hypothesis to provide more of 
a protective role in immunity to pathogens. Th17 can be protective for some 
bacterial pathogens but also more likely to promote autoimmunity.   
There are multiple avenues in which we might direct our efforts in 
elucidating every nuanced step from the HLA-II allelic variant itself to the 
biomolecular pathways intervening to produce caries. It is a complicated and 
complex task, but one in which opportunities abound. The more we learn about 
how HLA-II genes affect antibody response to critical epitopes, and the immune 
response in general, the better position we will be in to understand why some are 
more susceptible to caries than others, and the mechanism(s) by which caries 
may be inhibited. It is important to know that some allelic variants will 
predispose to caries and others will protect against it. In time, it will be 
important to identify those alleles that are protective (Xavier and Rioux, 2008), 
and employ a multidimensional model (Chang et al., 2008), including one that 
better approximates the oral microbiome (Filoche et al., 2010). A significant 
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opportunity ahead of us is to characterize the functional outcomes from 
polymorphisms that are associated with caries, either from previous literature or 
recent genome-wide association studies. Studying allelic variants within a 
specific diseased population is an excellent way to determine functional 
immunogenetic pathways (Xavier and Rioux, 2008).   
Conclusion 
Complex immunogenetic pathways involved in the caries disease process 
itself are not only crucial to understanding the fundamental nature of this 
infectious disease, but also essential in paving the way for new algorithms of 
diagnosis and detection (e.g., using biomarkers in lab-on-a-chip technologies to 
distinguish caries-susceptible and caries-resistant patients), vital for developing 
new therapeutic approaches (e.g., vaccines), and crucial in revealing common 
susceptibility alleles (i.e., shared genomics) across a range of distinct but 
mechanistically related (i.e., shared pathogenesis (Zhernakova et al., 2009)) 
infectious diseases. Although HLA-II pathways account for only one piece of the 
caries genomic puzzle, they may prove even more important than we have 
suggested. 
Dissertation Outline 
This dissertation is divided into five chapters. Chapter one (the current 
chapter) provides a general introduction describing caries and human genetics 
and lays significant groundwork to understand the HLA-II gene and caries 
connection. Chapter two describes our current understanding with regard to 
how bacterial cariogens produce disease and how mucosal immunity responds 
to cariogenic bacteria as well as the link between type 1 diabetes and caries. 
Chapter three describes and explains the materials and methods used for three 
studies (1 laboratory study and 2 clinical studies) we have conducted. Chapter 
four describes the results, in separate sections, of the 3 studies. Chapter five 
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discusses the findings of the 3 studies, in separate sections, and what they might 
mean with regard to HLA-II genes and caries. It also describes future directions 
for continuing research in this significant area. 
 16 
 
CHAPTER TWO 
  
The Symbiosis of the Human Microbiome 
All organisms function in the face of constant pathogenic threat, yet most 
continue to live and are protected from a variety of pathologies. Part of this 
protection in nature comes from symbiotic relationships. Take microrhizae, a 
fungal group that lives in symbiosis with the roots of plants, as it increases a 
root’s capacity to uptake water. In humans, the host-microbe symbiosis has 
produced the relative homeostasis we observe in host-commensal relationships. 
For example, we are born into the world germ free, yet thereafter grow and 
develop while 100 trillion microbes populate our intestinal tract (one of several 
microbiomes in our body) and we remain healthy (Ley et al., 2006). One 
experimentally corroborated instance of symbiosis in the human intestine 
involves Bacteroides fragilis, which not only regulates its multiple capsular 
polysaccharides, but is also able to thereby conduct the cellular and physical 
maturation of the developing immune system making it critical for host–bacterial 
symbiosis (Liu et al., 2008). One set of authors describe the overall picture of 
host-commensal symbiosis in the intestinal tract accordingly: 
These resident bacterial populations make a number of key 
contributions to host health, including enhancing digestive 
efficiency, promoting proper immune system development, and 
limiting pathogen colonization. In return, resident microorganisms 
derive benefit from association with their hosts by inhabiting a 
protected, nutrient-rich environment. Thus, these host-microbial 
associations constitute a mutually beneficial symbiosis (Duerkop et 
al., 2009). 
 
The notion of symbiosis is not novel, but was postulated over a century ago 
(Carroll et al., 2009; Metchnikoff and Mitchell, 1908) by the 1908 Nobel Laureate 
in Physiology or Medicine, Ilya Ilyich Mechnikov. The host-pathogen 
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relationship is different in that deleterious outcomes follow, and under particular 
conditions host-opportunistic relationships will also lead to infection or disease 
(Virgin, 2007).   
 Despite the benefits and fact of symbiosis, it is thought that the 
microbiomes associated with humans are relatively narrow in scope when 
compared to all earthly possibilities. Of the total divisions (deep evolutionary 
lineages) of bacteria that exist, only 4 percent of those divisions populate the 
gastrointestinal microbiome. Additionally, only 8 percent of the Archaea 
divisions are naturally harbored, indicating that there are definite limits to 
symbiosis (Ley et al., 2006). Still, the numbers here are perhaps not quite as 
important as the fact that symbiotic relationships naturally exist. Only 1 out of 
every 10 cells in our body is eukaryotic. The other nine are prokaryotic, helping 
us to understand that the human microbiome is something we cannot overlook. 
 There is a continuing debate over how microbes that colonize the host 
become pathogenic or remain symbiotic. Many believe the microbial niche is 
altered by environmental cues enabling new colonizers access; or that these cues 
somehow stimulate changes in the biological activity of commensals, leading to 
infection or disease (Avila et al., 2009). Due to its abundance, others hold that the 
commensal microbiota protects the human microbiome from pathogenic 
organisms that are actually living among the commensals, but at such low 
thresholds that their ability to infect is thwarted. Both of these scenarios most 
certainly play out to one degree or another in both pathogenesis and symbiosis, 
but also fundamental to these questions is the influence of host genetics on the 
microbiome. 
Human Genetics Regulate Composition of Microbiome 
 It has now been demonstrated that host genetics play a major role in 
determining the composition of the intestinal microbiome (Khachatryan et al., 
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2008). Moreover, it has also been shown that host genetics influence the 
gastrointestinal microbiome of mice (Toivanen et al., 2001). Interestingly enough, 
the murine H-2 region, corresponding to the HLA region in humans, is what was 
pinpointed as having a predominant affect on the intestinal microbiome of mice. 
Twin studies in humans also demonstrate the strong influence host genetics has 
on the intestinal microbiome (Stewart et al., 2005). A much older study has also 
suggested that the nasal microbiome is genetically regulated (Hoeksma and 
Winkler, 1963). More recently, others have demonstrated that the oral 
microbiome is also genetically modulated (Corby et al., 2007; Corby et al., 2005). 
Significantly, a number of studies suggest that HLA-II genes (as well as other 
HLA and host genes), are involved in determining the composition of the human 
microbiome, especially perhaps with regard to tolerance of commensal bacteria 
or activation against pathogenic bacteria (Azuma et al., 1994; Cario, 2008; De 
Palma et al., 2010; Klein et al., 2009; Mohammadi et al., 1996; O'Mahony et al., 
2008), a point that we will return to.  
Diversity of the Oral Microbiome 
Although the human gastrointestinal microbiome has been of great 
interest, so too have the ocular (Miller and Iovieno, 2009), nasal, oral (Filoche et 
al., 2010), urogenital, and skin (Gao et al., 2007) microbiomes become areas of 
focus (McGuire et al., 2008). Researchers in all of these areas have begun 
sequencing the existent microorganisms and much work is being done to 
understand how biofilms protect and predispose to disease.  Actually, it was the 
microorganisms in the oral microbiome that were most readily accessible and 
first studied in 1683 (Avila et al., 2009). Anthony van Leeuwenhoek, a self-made 
scientist who was not bound by the traditions of the academy, wrote to the Royal 
Society describing some of the first observations ever recorded on living bacteria. 
Leeuwenhoek observed Streptococcus commensals, pathogens and opportunists. 
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In the case of caries, the prototypic pathogen is S. mutans (Ajdić et al., 2002; 
Nakano et al., 2007; Ooshima et al., 1981; Vinogradov et al., 2004), although it is 
certainly not the only one (Russell, 2008). Indeed, Leeuwenhoek beheld an array 
of microorganisms. In fact, the oral micriobiome is probably the most diverse and 
unique microbiome in the human body (Kreth et al., 2009) as it is the gateway to 
the rest of the body and faces more extreme perturbations than any other human 
microbiome (Avila et al., 2009).  
For instance, the number of species-level phylotypes (phylogenetic type) 
or species in the oral cavity has now been determined to be almost 20,000 (Keijser 
et al., 2008) using a well established standard. This standard indicates that when 
“clusters of related 16S rRNA gene sequences” are  “characterized by levels of 
pairwise sequence identity” at or above 97 percent, they represent the same 
species (Ley et al., 2006). Otherwise, they represent distinct phylogenetic types or 
species. Additionally, according to other well respected standards (Sogin et al., 
2006), the number of species in the oral cavity may be closer to 26,000, and that 
only accounts for perhaps 50 percent of the overall microbiota (Keijser et al., 
2008). Either of these numbers exceeds the total numbers of commensal species 
populating the skin (hundreds) and gut (thousands; although these figures are 
likely higher), and the larger number represents more than 65 percent of what 
others have found in the deep marine biosphere (Sogin et al., 2006), where we 
would expect biodiversity to far outstrip the more narrow diversity in humans.  
All of these facts highlight the incredible diversity of the oral microbiome 
despite the fact that one recent article incorrectly equates the oral microbiome to 
the salivary microbiome (Carroll et al., 2009), thus vastly underestimating by at 
least 5-fold (Keijser et al., 2008), the total number of resident microorgisms found 
there. For example, the oral microbiome may be divided into more specialized 
microbiomes (Aas et al., 2005; Kreth et al., 2009), such as the tooth surface 
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microbiome, the salivary microbiome (Nasidze et al., 2009), and the soft tissue 
microbiome. By not including the soft tissue and tooth surface microbiomes, one 
would greatly underestimate the composition and diversity of the oral 
microbiome. Whatever the divisions, the principles of symbiosis or pathogenesis 
are similar.  
Commensals and Streptococcus mutans in Oral Microbiome      
In plaque samples alone (i.e., tooth surface microbiome), 10,000 different 
species have been identified. Nonetheless, 1,000 of these species reportedly make 
up at least 90 percent of the total population (Keijser et al., 2008). It is important 
to note that although the previous numbers are very large, a vast number of 
these species remain clinically insignificant (even taking into account the 
theoretical framework of the microbiome) and are found in only trace amounts. 
Thus, the field of significant oral microbial players narrows substantially. More 
than 80 percent of early colonizers in the plaque and mucosa (Avila et al., 2009) 
are oral streptococci (Kreth et al., 2009). The oral streptococci are very important 
(either symbiotically or pathogenically) in the oral microbiome and can be 
divided into 5 groups, including Mutans, Salivarius, Anginosus, Sanguinis, and 
Mitis. In humans, the Mutans group, otherwise called mutans streptococci, is 
made up of Streptococcus mutans and Streptococcus sobrinus, both of which have 
been associated with caries (this group also includes S. downei (macaques), S. ratti 
(rats), and S. criceti (hamsters), which are all associated with caries); the former 
continues to remain the prototypic caries pathogen, and no other species within 
the oral microbiome “is yet a serious contender to S. mutans for a role as a 
worthwhile marker organism” in the caries process (Russell, 2008). 
Streptococcus mutans in the Ecological Pathogenesis of Caries  
In order for a caries pathogen to lead to the disease, four broad categories 
must be met. The tooth biofilm must begin to form (e.g., after cleaning the tooth 
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surface), which occurs via adhesin-receptor interactions. An accumulation or 
aggregation of pathogenic microbes must reach a particular deleterious 
threshold. These microbes must be acidogenic, meaning that they will 
metabolically produce acid. Finally, they must also be aciduric, meaning that 
they will grow and metabolize under very low pH. These essential requirements 
must occur within the framework of the biofilm staying at an acidic pH for 
enough time to alter the composition of the flora in favor of aciduric species, 
since those species that are less acid-resistant typically produce a more alkaline 
dynamic. S. mutans can and does fulfill all of these requirements as it interacts 
with other members of the oral microbiota.       
Streptococcus sanguinis and Streptococcus gordonii of the Sanguinis group 
are some of the first oral streptococcal species to colonize the native tooth 
structure (Kreth et al., 2009). It is interesting to note that both of these species 
express adhesins with virtually identical binding profiles, thus creating a 
competitive environment for the same host receptors at the same time. Although 
S. sanguinis is more prevalent in plaque and saliva than S. gordonii, S. gordonii 
competes more effectively with S. sanguinis for tooth structure than any other 
oral streptococci that have been tested. Thus, both of these early colonizers have 
a significant impact on biofilm formation. One study demonstrated that these 
commensals (S. sanguinis, statistically significant; S. gordonii, high but not 
statistically significant) are intimately involved in host-symbiotic relationships 
(Becker et al., 2002). In caries-free hosts, the oral microbiome was dominated by 
S. sanguinis in relation to S. mutans, which protected these individuals from these 
and other pathogenic microbiota gaining advantage. In hosts that were 
susceptible (manifesting a severe form of caries), the oral microbiome was 
virtually erased of S. sanguinis and S. mutans dominated the landscape.  
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 How might this happen? S. mutans must attach to the host tissue in 
earnest by multiplying and metabolizing nutrients available, thereby lowering 
the pH of the biofilm. Thus displacing acid-susceptible species until the biofilm 
has achieved an acidic state, which leads to demineralization of the tooth 
structure. In an immunogenetically deficient host, one example of how S. mutans 
does this is to produce bacteriocins (mutacin I and mutacin IV), which inhibit the 
growth of both S. sanguinis and S. gordonii (Kreth et al., 2009). Bacteriocins of S. 
mutans may act on other genera as well although their activity is typically 
confined to Gram-positive bacteria  (Corr et al., 2007). Neither streptocin nor 
sanguicin (the bacteriocins respectively produced by S. gordonii and S. sanguinis) 
are capable of targeting S. mutans. Thus, in vying for a niche in the oral 
microbiome, S. mutans proves a formidable foe. These commensals, however, do 
have somewhat of an advantage during intial colonization. They produce 
hydrogen peroxide (H2O2), which is oxygen (O2) dependent. Because the 
biofilm’s density early on in colonization is low, the O2 tension is sufficient to 
allow aerobic respiration, thereby preventing S. mutans from invading. However, 
once the microbial density reaches a particular threshold, S. mutans bacteriocin 
genes are triggered and expressed while the bacteriocins from these other 
commensals are ineffective against their major foe. Since bacteriocins are most 
effective in a mature biofilm, S. mutans has the competitive advantage over S. 
gordonii and S. sanguinis and is one reason this formidable pathogen can begin to 
initiate changes in the microflora. Almost 90 percent of S. mutans isolates 
produce mutacins, suggesting that this is evolutionarily important to the species.  
 Another example of how S. mutans can penetrate the oral microbiome is 
its mutualistic relationship with a gram-negative early colonizer, Veillonella 
atypica (Kreth et al., 2009). These two seem to do better when the other is around. 
V. atypica uses lactic acid (an organic acid), which S. mutans produces 
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prodigiously, as an energy source since it cannot metabolize fermentable 
carbohydrates. Moreover, V. atypica seems to detoxify the environment for S. 
mutans. But there actually seems to be a more significant reason. Together, they 
become much more resistant to antimicrobial attack (thus nullifying the 
antimicrobial protein-effect in the context of mucosal immunity, which will be 
discussed later in this chapter) and the transcription profile of S. mutans changes 
significantly to accomplish presumably very important survival functions within 
the oral microbiome. 
 A final theme of the most important step in penetrating the oral 
microbiome is what happens when S. mutans attaches to the host tissue in the 
first place. It has been firmly established that Streptococcus adherence to host 
tissues is almost exclusively mediated by surface proteins (Nobbs et al., 2009). In 
the case of S. mutans, there are 3 surface proteins of major importance, two of 
which have been briefly mentioned, with regards to attaching to the tooth 
surface. These include glucosyltransferases (GTFs), glucan-binding proteins 
(GBPs), and I/II. All of these proteins have been vaccine targets for caries, 
vaccines that remain elusive. GBPs are surface-associated adhesins that play a 
substantial role in architectural development of the biofilm, GTFs are cell-
associated secreted protein enzymes, and I/II is a cell-wall anchored adhesin.  
In biofilm development, insoluble polysaccharides (these moieties are 
formed by GTF hydrolytic cleavage of sucrose into fructose and glucose, which 
are then polymerized) are essential, but they do not facilitate initial attachment to 
the salivary pellicle unless GBPs are present there. Thus, there are two processes 
of attachment, sucrose-dependent and sucrose-independent, respectively. I/II fits 
into the latter category and is thus very important since it can attach to the 
acquired pellicle without another factor needing to be present. I/II is firmly 
anchored to the cell wall by sortase A (SrtA) (Marraffini et al., 2006), which is 
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also ubiquitous in virtually every species of Streptococcus although there are 5 
currently known sortases in the sortase family of transpeptidases. The acquired 
tooth pellicle is made up of an array of omnipresent salivary proteins such as 
acidic proline-rich proteins or salivary glycoproteins, such as glycoprotein-340 
(gp340, otherwise known as salivary agglutinin [SAG] or Deleted in Malignant 
Brain Tumours 1 [DMBT1]). Human gp340 belongs to the family of innate 
immune proteins, which are mainly comprised of scavenger receptor cysteine-
rich (SRCR) proteins. There are SRCR domains along the entire length of gp340, 
which serve as theoretical binding sites for the specific arrangement of particular 
regions within I/II. When in the planktonic form, SRCRs provide gp340 the 
ability to serve as a pattern recognition receptor (PRRs are discussed later) 
(Loimaranta et al., 2009). Thus, gp340 “promotes bacterial aggregation and 
clearance” when it encounters S. mutans planktonically, however, if the 
glycoprotein is embedded in the tooth pellicle (i.e., immobilized), it instead 
serves as the receptor in receptor-adhesin streptococcal attachment (Nobbs et al., 
2009).  
The Ingbritt strain of S. mutans, as well as other streptococcal species, has 
been shown to bind a very specific region of gp340, namely SRCR2 (there are 14 
SRCR domains along the length of gp340) (Bikker et al., 2002). I/II is also 
extremely adept at adhering to an array of host and environmental receptors, as 
has been demonstrated in the cases of “collagen, [fibronectin], laminin, and other 
oral microorganisms,” such as, “Actinomyces naeslundii, S. oralis, Porphyromonas 
gingivalis, and Candida albicans” (Nobbs et al., 2009). Thus, S. mutans can not only 
directly bind to the conditioned acquired pellicle, through gp340 interactions, it 
can also bind directly to other microbes populating the pellicle surface. Once 
attached, S. mutans has a biologically competitive advantage under a variety of 
circumstances as previously mentioned. Once I/II has facilitated the attachment 
 25 
 
of S. mutans to the tooth pellicle, it also “influences biofilm formation, promotes 
collagen-dependent bacterial invasion of dentin, and mediates adherence to 
human epithelial cells” (Larson et al., 2010).           
Host Immunogenetic Responses to a Caries Pathogen 
The key thus far is that if a dental pathogen such as S. mutans begins to 
change the oral microflora, it is because it has first attached to the community 
(biofilm) and then displaced other commensals. This could be prevented if it was 
attacked early on during colonization or planktonically neutralized. There are 
perhaps different host immunogenetic profiles that allow such insertion and 
expansion of S. mutans into the microflora until the host is overwhelmed, and 
other profiles that respond immunologically early in the process, thus keeping S. 
mutans levels low. In the oral cavity, these profiles are functionally manifested at 
the level of mucosal immunity.  
The mucosal immune system, which acts at mucosal surfaces, in contrast 
to the systemic immune system, is dominated in its secretions by one particular 
immunoglobulin (Ig) isotype, secretory IgA (SIgA). IgA is the most plentiful 
immunoglobulin in mammals (Macpherson et al., 2000) and makes up more than 
70 (or perhaps more than 75) percent of all Ig produced (Macpherson and Slack, 
2007; Macpherson et al., 2008). There is also evidence that SIgA not only plays a 
major role in adaptive immunity, but also in innate immunity (Macpherson et al., 
2008). Considering that the IgA:IgG ratio in oral secretions from the parotid 
gland is 500 times greater than that of serum, and that IgA-positive (IgA+) plasma 
cells (PCs), in comparison to the parotid gland, are double and triple the density 
in the submandibular and labial glands, it is clear how important this Ig is in the 
oral microbiome (Brandtzaeg, 2007). It is also very important in the instestinal 
microbiome, since the colonization of commensals serves as a necessary 
requirement and is modulated by SIgA induction at mucosal surfaces 
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(Macpherson et al., 2000). The entire mucosal immune system across the entire 
human microbiome revolves around SIgA, and without it the pathogenic threat 
all mammals have encountered since birth would be insuperable. 
 A majority of the evidence demonstrates an “inverse relationship” 
between caries and levels of salivary IgA in children and young adults 
(Brandtzaeg, 2007), meaning that someone highly susceptible to caries would 
have low levels of  salivary IgA and someone more resistant would have high 
levels of salivary IgA. This summary statement must be understood in its 
context.  There are many things to consider and understand if we are to 
ultimately know how host immunogenetics modifies the oral microbiome in the 
context of mucosal immunity. Innate and adapative immunity are involved, the 
nexus between them, and HLA genetics. Thus, these connections are essential 
(especially in terms of context) to understand how the proposed hypothesis 
purported in these pages may function in humans.  
Innate Immunity 
 The difference between innate and adaptive immunity are the receptors 
that mediate their responses, pattern recognition receptors (PRRs) in innate 
functionality, and antigen receptors in the case of adaptive immunity 
(Medzhitov, 2007). Every immune cell in this system has a host receptor, a PRR, 
whose target ligand is typically a pathogen-associated molecular pattern(s) 
(PAMPs), even though pathogens, commensals and opportunitsts all express 
PAMPs. “Bacterial PAMPs are often components of the cell wall, such as 
lipopolysaccharide [LPS], peptidoglycan, lipoteichoic acids and cell-wall 
lipoproteins.” It is important to note here that PRRs cannot discriminate between 
pathogens and other benign colonizers, yet they are essential in maintaining 
homeostatic symbiosis in a way that remains ambiguous.  
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 There are two broad categories of PRRs, namely transmembrane receptors 
found on the cell surface (including endosomal receptors) and intracellular 
receptors (Medzhitov, 2007). One well known class of transmembrane receptors 
is the Toll-like receptors (TLRs) that recognize viruses, but more important for 
our focus, bacterial products such as LPS and lipoteichoic acids (Akira et al., 
2006). We know that TLRs, once bound to their ligands, activate an array of 
antimicrobial responses, albeit indirectly in humans. Another class of PRRs, the 
Nod-like receptor (NLRs), which are intracellular receptors, recognize bacterial 
products within the cell and posses a nucleotide-binding oligomerization domain 
(NOD). NOD proteins as well as other subfamilies of NLRs, such as NALP 
(NA
Adaptive Immunity 
CHT-LRR-PYD-containing protein; see later discussion) or NAIP (neuronal 
apoptosis inhibitor protein), have not been well characterized with regard to 
antimicrobial effect, but are nonetheless implicated in responding to bacterial 
infection. We shortly return to the connection between adaptive and innate 
immunity.  
 The acquired or adaptive immune system is mediated by two antigen 
receptors, the T cell and B cell receptors. There are also two types of lymphocyte, 
both of which carry these types of receptors, namely the conventional 
lymphocytes and the innate-like lymphocytes (some have even labeled them 
simply innate lymphocytes). The traditional lymphocytes are T cells and B cells. 
These T cells are mainly alpha, beta T cells (αβ T cells) while the B cells are 
mainly B2 (bone marrow-derived) cells whose antigen receptors are essentially 
built randomly (Medzhitov, 2007). In contrast, the architectural scaffolding of 
innate-like lymphocytes is not random but restricted, yet these lymphocytes, 
consisting of some gamma, delta T cells (γδ T cells), natural-killer T cells (NKT 
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cells), B1 cells (pleuroperitoneal cavities), and splenic marginal zone B cells, are 
the counterparts of the conventional lymphocytes.  
 Among the conventional αβ T cells, there are two types, including T-
helper cells (characterized by the co-receptor CD4) and cytotoxic T cells 
(characterized by CD8), which recognize HLA-II and I molecules respectively, 
positioning these cells to provide an almost limitless ability to recognize diverse 
antigens (Medzhitov, 2007). B2 cells can also recognize a multitude of antigenic 
epitopes. We will return to how conventional lymphocytes specifically function 
in the context of mucosal immunity in relation to the proposed hypothesis.  
Although B1 cells cannot survey as wide a variety of antigens as their 
traditional counterparts, they are nonetheless significant in their own right. 
Though they are generally thought to secrete IgM in response to commensal 
bacteria (and self antigens), experiments conducted by Macpherson et al. and 
others (Fagarasan et al., 2001; He et al., 2007; Uematsu et al., 2008) confirm that 
these cells produce a prominent SIgA response in a T cell-independent (TI) and 
follicularly organized lymphoid tissue-independent manner, needing only 
intestinal lymphoid aggregates containing these B cells and antigen to activate 
(Macpherson et al., 2000) the mucosal response. TI pathways serve as the first 
line of defense during which the adaptive response can initiate and ultimately 
provide protective immunity by high-affinity SIgA (Dullaers et al., 2009). It is 
interesting to note that innate-like T cells identify with HLA-Ib proteins, and one 
protein in this category is MR1 (MHC-related protein I). In a specific case, a 
unique mucosal innate T cell called mucosal-associated invariant T cell or MAIT 
is speculated to serve as an intestinal regulator of SIgA production (Huang et al., 
2008). Surprisingly, the non-classical HLA-I protein, MR1, is not dependent upon 
the HLA-I peptide loading complex, but instead relies greatly on an HLA-II 
antigen presentation pathway. Thus, it putatively allows this HLA-related 
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protein to sample endocytosed microbial antigens (the presumed APCs are B 
cells), thereby activating MAITs and the immune response. Finally, it is 
interesting to note that some non-classical HLA molecules  
might themselves be ligands for T-cell receptors, without 
presenting any other molecules. In this case, the expression of these 
molecules is thought to be inducible by the engagement of PRRs 
[e.g., TLRs] on specific cell types, such as mucosal epithelial cells 
(Medzhitov, 2007). 
 
The Innate-Adaptive Nexus 
Innate and adaptive immunity come together at the interface between 
PRRs recognizing PAMPs and antigen-lymphocyte interactions (Medzhitov, 
2007). This nexus is represented by both T-independent and T-dependent 
antigens. For the latter, dendritic cells interpret PAMPs for T cells by initially 
sensing the pathogen via TLRs (or other PRRs such as NLRs) to upregulate the 
HLA-II pathway, and then presenting the processed antigen to TCRs via surface 
HLA-II molecules. For the former, this interface is directly represented by an 
antigen physically interacting with a PAMP (presumably by Fc receptor-antigen 
and PRR-PAMP co-engagement). In addition to conventional B lymphocytes, B1 
cells may directly interact with PRRs thereby initiating SIgA secretion against 
bacterial antigens, in the same vein as the aforementioned TI pathway example. 
Additionally, innate-like T cells do recognize antigen presented by non-classical 
HLA molecules. In particular cases, these T cells do not need a peptide in the 
binding groove of these HLA molecules (PRR-induced) to initiate an immune 
response. As previously stated and as is widely accepted, T-helper cells are 
activated by dendritic cells or other antigen presenting cells even when antigens 
and PAMPs are not directly linked, thus initiating the adaptive response for 
long-term protective immunity. This immune response is the end-game of 
mucosal immunity.  
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Mucosal Immunity  
The mucosal immune system is inextricably involved with the microbes it 
encounters (e.g., caries pathogens), SIgA (as explained earlier), and the host’s 
HLA immunogenetics. Let us follow a caries pathogen, S. mutans, on its journey 
through the human microbiome, and the microbiome’s regionalized mucosal 
immune system, in order to discuss how it relates to SIgA and HLA-II genetics.  
S. mutans can be vertically transferred from mother to child or from adult 
to adult. Once S. mutans gains access to the human microbiome orally, its journey 
is complex and dynamic. Some bacterial siblings may localize to the tooth surface 
pellicle close to the gingival margin of the dentition or the variegated oral 
mucosa, while other S. mutans may localize to the lingual or palatine tonsils 
(oropharynx), or even the pharyngeal tonsil (nasopharynx), which together are 
sometimes referred to as Waldeyer’s tonsillar ring, Waldeyer’s pharyngeal ring, 
or simply Waldeyer’s ring. In the context of mucosal immunity, however, this 
specialized region with its specialized lymph tissue is called the naso-
oropharynx- or nasopharynx-associated lymphoid tissue (NALT). NALT is an 
important inductive site for SIgA in the salivary glands, but we will return to 
that theme later.  
Although many an S. mutans bacterium will localize to the oral 
microbiome and NALT, others will be carried away planktonically during 
swallowing and inferiorly traverse the gastrointestinal (GI) tract by passing over 
the Laryngopharynx (laryngeal inlet closes during swallowing), moving through 
the Esophagus and esophageal sphincter into the acidic stomach where S. mutans 
can survive because of its aciduric nature. Moving through the pylorus into the 
duodenum, then into the jejunum, S. mutans finally moves into the distal ileum 
where it encounters a foci of mucosa-associated lymphoid tissue (MALT), a 
general term that refers to any principal inductive site for mucosal immunity in 
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any of the mucosal compartments of the body, which in this anatomical case is 
the gut-associated lymphoid tissue (GALT).   
GALT consists of 3 types of inductive sites, including Peyer’s Patch, the 
appendix, and isolated lymphoid follicles (ILFs) (Brandtzaeg et al., 2008). These 
inductive sites posses all the necessary cells (T-cells, B-cells, and antigen 
presenting cells) to generate a mucosal immune response (Kiyono and 
Fukuyama, 2004). Peyer’s Patches (PPs) are quintessential immune inductive 
sites and are most dominant in the ileum. In early male adolescence, for example, 
approximately 61 percent of all PPs in the small intestine are located in the ileum, 
in contrast to only 37 percent in the jejunum, and 2 percent in the duodenum 
(Cornes, 1965). At birth, 78 percent of all PPs in the small intestine in males are 
located in the ileum, whereas only 22 percent reside in the jejunum, and are 
virtually non-existent in the duodenum. The main components of PPs are 
follicles whose residents include T and B cells (Makala et al., 2002). Between the 
follicles is the interfollicular area (or interfollicular region, IFR) that houses high 
endothelial venules (HEVs), which are made up of specialized endothelial cells 
that lymphocytes selectively bind to (these cells are taller and more cuboidal in 
appearance than their morphologically flat endothelial counterparts) (Johnson-
Léger et al., 2000), and T lymphocytes. Above a follicle is a dome comprised of 
plasma cells and T and B cells, which is overlaid by what is termed the follicle-
associated epithelium (FAE) that interfaces with the intestinal lumen. PP mucosal 
epithelium (i.e., FAE) is specialized in that it contains membrane or microfold 
(M) cells that play a major role in transferring antigen across (antigen 
transcytosis) the mucosal barrier. Thus, PPs in the small intestine and especially 
in the distal ileum serve as major surveyors of both symbiotic and pathogenic gut 
bacteria. If S. mutans has managed to escape immunological recognition before it 
arrives at the distal portion of the ileum, it is likely that the ileal patchwork of 
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inductive sites will recognize this dental pathogen and trigger the appropriate 
immune response, thus leading to SIgA in the compartment of the oral 
microbiome. 
M cells have long been known to facilitate the internalization of antigen to 
PPs in GALT. Today, we know that they posses specialized receptors which 
facilitate glycoprotein 2 (GP2)-mediated transcytosis of bacterial antigens (Hase 
et al., 2009). One piece of evidence for this is that in ileal FAE GP2 receptors are 
highly expressed while their expression decreases exponentially in the villus 
epithelium. These results from the human (and murine) small intestine also hold 
for M cell GP2 receptors expressed in human NALT (Hase et al., 2009; 
Verbrugghe et al., 2008). M and intestinal epithelial cells intrinsically posses 
TLRs located on their apical surfaces, which help recognize PAMPs. TLRs are 
also coupled with intracellular adaptor proteins in most TLR-mediated signaling, 
and the protein almost always involved is called MyD88 (myeloid differentiation 
factor 88) (Brandl et al., 2007). TLR-mediated signaling initially induces epithelial 
secretion of a protein called RegIIIγ, which can directly kill Gram-positive 
bacteria (Pamer, 2007) like S. mutans in the short-term, but cannot ensure long-
term protective immunity. Thus, the basic innate functions of the mucosal 
barrier, and especially PPs, involve M and mucosal epithelial cell TLRs (coupled 
with MyD88) recognizing PAMPs of S. mutans, and signaling not only the innate 
release of antimicrobial proteins, but also the activation of adaptive dendritic 
cells (DCs) making them immunogenic (Blander and Medzhitov, 2006). It is now 
known that DCs can extend their dendrites across tight junctions inter-
epithelially to directly survey bacteria, in this case S. mutans, in the intestinal 
lumen, but this is also enhanced by TLR signaling (Maynard and Weaver, 2009). 
M cells appear to preferentially express TLR1, TLR2 and TLR4 as these TLRs are 
highly expressed relative to other M cell counterparts, namely the villus 
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epithelium and FAE (Cashman and Morgan, 2009). Interestingly, one study has 
suggested that S. mutans clearance is inhibited by the lack of TLR2 (Horst et al., 
2009). In certain cases, TLR2 has been specifically linked to Th2-associated DC 
stimuli although there are certainly other mechanisms (MacDonald and Maizels, 
2008). M cells recognize and transcytose pathogens such as S. mutans from the 
ileal lumen to an infolding of their basolateral membrane forming a pocket in 
which DCs (macrophages, and T and B cells also reside in close proximity) can 
endocytize S. mutans and present immunodominant antigens on its surface to T 
cells in the T-cell rich IFR. 
Antigen Presentation  
DCs are the most potent APCs in adaptive mucosal immunity. All subsets 
of DCs in the subepithelial dome (SED), and elsewhere in PPs, express HLA-II 
(Mercado-Lubo and McCormick, 2010), but one set (termed LysoDC) located in 
the SED and FAE expresses an extremely high level of HLA-II molecules 
(Lelouard et al., 2010), thus playing a crucial role in antigen presentation in the 
adaptive immune response across the mucosal barrier. It is interesting to note 
that ileal intestinal epithelial cells (which would include M cells) constitutively 
express HLA-II molecules (Buning et al., 2008) as well as lamina propria (LP) 
stromal cells, both of which may present antigen as non-professional APCs to T 
helper cells. In any case, antigen presentation occurs and initiates the adaptive 
immune response.  
The immunodominant antigen of S. mutans, I/II, which is responsible for 
bacterial attachment to the tooth surface, is one of the major antigens that is 
processed and presented by DCs to T cells in the IFR in our scenario. Both the 
intracellular process and the actual presentation of I/II is modulated by particular 
biologically-related and HLA-II genes. After discussing these genes, I will 
describe the movement of I/II to intracellular locations of the APC to be 
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degraded, HLA-II ligation to I/II peptides, and the final trafficking of HLA-II-I/II 
peptide complexes to the APC surface. 
HLA-II Transcriptional Regulation 
It is very important here to recognize the nexus between innate and 
adaptive immunity as that interface is very important with regard to HLA-II 
expression in DCs (and other immune cells)—at the gene level. All structural 
genes have promoter or initiation sites, at which point along the DNA, RNA 
polymerase begins to synthesize messenger RNA (i.e., transcription). This 
ultimately leads to protein assembly (i.e., translation), and in this case, the α and 
β chains of HLA-II molecules that form the peptide binding groove. Because 
HLA-II molecules are constitutively expressed in DCs, and other immune cells 
already mentioned, there is a basal level of HLA-II transcription in these cells. 
Nonetheless, transcription factors greatly increase the production rate of mRNA 
and therefore the rate of HLA-II production, and enhancers also stimulate 
promoters. But transcription factors and enhancers can only be activated in 
response to a stimulus.  
An important gene, CIITA (class II [meaning HLA class II] transactivator), 
is inextricably tied to regulating HLA-II transcription upregulation through its 
protein, which is a non-DNA-binding co-activator (Reith et al., 2005). I will 
briefly explain how this works. Upstream of the gene region encoding the HLA-
II molecule is the promoter and also a regulatory module currently identified as 
composing 4 unique sequences or boxes, labeled in the 5’ to 3’ direction as S, X, 
X2, and Y. Each box in this regulatory module, initially known as the SXY 
module, can bind to ubiquitously available transcription factors. The currently 
known SXY binding factors include:  
the heterotrimeric X-box-binding factor regulatory factor X (RFX), 
which is composed of RFX5, RFX-associated protein (RFXAP) and 
 35 
 
RFX-associated ankyrin-containing protein (RFXANK); the X2-box-
binding factor cyclic-AMP-responsive-element-binding protein 
(CREB); the Y-box-binding factor nuclear transcription factor Y 
(NFY); and an as-yet-unidentified S-box-binding factor (Reith et al., 
2005). 
 
Once RFX, CREB, and NF-Y (made up of 3 subunits NF-YA, NF-YB and NF-Y) 
(Leimgruber et al., 2009) have bound the SXY (now simply termed S-Y) module 
(Krawczyk and Reith, 2006), the entire protein complex is referred to as the HLA-
II enhanceosome, and serves as a docking site for CIITA, which in turn, will 
recruit other necessary factors in activating HLA-II transcription. 
 As previously mentioned, stimuli must precede the binding of 
transcription factors to the S-Y module and the docking of CIITA. Of note here is 
the fact that CIITA has certain structural properties that fit into the context of 
PRRs, more specifically NLRs, which recognize PAMPs as previously discussed. 
As heretofore mentioned, there are two broad categories of PRRs, namely 
transmembrane receptors such as TLRs, and intracellular receptors such as 
NLRs. TLRs possess Toll–interleukin 1 receptor (TIR) domains (or alternatively 
called (IL)-1R homology domains), which extend into the cytoplasm of the cell 
and appear to be a link between TLRs and NLRs when they synergistically work 
in initiating an immune response to bacteria (Werts et al., 2006). For example, 
MyD88-dependent TLR signaling and Nod2 (an NLR) work together in initiating 
immune responses. NLRs involve four domains:  
an N-terminal effector domain, which can be a pyrin domain 
(PYD), a CARD [caspase activation and recruitment domain] or a 
Bir [baculovirus ‘inhibitor of apoptosis’ repeat] domain; a central 
NACHT domain (NACHT stands for domain present in Naip, 
CIITA, HET-E (plant het product involved in vegetative 
incompatibility) and TP-1 (telomerase-associated protein 1)); [a 
NOD domain] and a C-terminal LRR domain thought to constitute 
the microbe-sensing portion (Fritz et al., 2006). 
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Thus, NLRs are comprised of effector (PYD, CARD, or Bir), NACHT, NOD, and 
LRR domains. It seems that NLRs work in tandem or synergistically with TLRs 
thus bridging the extracellular and intracellular compartments and providing for 
DC activation in the face of antigens such as I/II. For example, TLRs have been 
reported to signal through NALPs (a subfamily of NLRs) for Gram-negative 
bacteria, and Nod2 (another NLR) has been linked to signaling immune 
upregulation against Gram-positive bacteria, such as S. pneumonia (Fritz et al., 
2006), which possesses an antigenic region homologous to a region of the 
proline-rich area of I/II. CIITA, which is found in DCs, contains CARD, AD 
(activation domain), NACHT, NOD, and LRR domains. Similarly, Nod2 has the 
exact same structure minus AD. Thus, CIITA possesses the ability to recognize 
PAMPs and other signals in order to initiate transcription through a promoter 
(called pI) mainly active in DCs (Reith and Boss, 2008). Once CIITA has been 
transcribed and translated, CIITA can dock in the HLA-II enhanceosome and 
finish recruiting the final factors essential for HLA-II synthesis.           
A defect in any of the HLA-II-biologically related genes, including CIITA 
leads to the severe consequences of bare lymphocyte syndrome, including the 
absence or virtual abolishment of antibodies to microbial antigens (100 percent 
prevalence) due to complete absence of HLA-II expression (Krawczyk and Reith, 
2006). This means that if all factors are present, then HLA-II molecules will be 
synthesized appropriately. Defects in immune recognition can arise from HLA-II 
structural gene variations as well as transcriptional gene defects. DCs interpret 
PAMPs for T cells by internalizing S. mutans via TLR-signals (and/or other PRRs 
such as NLRs), to upregulate HLA transcription factors and CIITA in the HLA-II 
pathway, any alterations in class II display of I/II to TCRs may arise due to allelic 
variations in class II molecules. This notion is further bolstered because the 
promoter genes that control HLA-II transcription are not combinatorially 
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regulated as is the case in many other human genes, but are controlled by CIITA. 
Moreover, the exact same genetic transcription machinery is used in synthesizing 
HLA-DM and HLA-DO, which are important intracellular processors of HLA-II-
peptide complexes (discussed shortly), as well as Invariant chain (Ii), which is 
also very important in regulating HLA-II-peptide loading (discussed shortly). 
Thus, differences in immunity against S. mutans will not manifest themselves in 
all-or-nothing ways but in more nuanced degrees of immunodeficiency or 
immunogenicity. 
HLA-II Endocytic Pathway and Trafficking 
 The α and β proteins, which are encoded by separate HLA-II genes, are 
assembled in the endoplasmic reticulum (ER) thus creating the HLA-II molecule 
that will ultimately project from the cell surface and present I/II peptides in the 
binding groove to TCRs. However, a chaperone protein, Ii, is actually assembled 
concomitantly with both chains and not only stabilizes their conjoined structure, 
but also prevents immature and inappropriate antigen binding (Berger and 
Roche, 2009). The nascent αβ-Ii complex travels from the ER and traverses the 
trans-Golgi network (TGN) toward the endosomes.  
 Once the HLA-II-Ii complex has arrived in endocytic organelles, Ii is 
proteolytically processed and released from class II to permit the binding of 
antigenic peptides (Berger and Roche, 2009). In endosome and lysosome 
microenvirons, resident proteases such as cathepsins S and L, degrade Ii in a 
stepwise fashion until all that is left is a peptide fragment, CLIP (class-II-
associated invariant chain peptide), which resides  in the HLA-II binding groove. 
An HLA-II molecule, HLA-DM, which does not present antigen on the surface of 
the DC, but rather functions in endosomes, directly binds the HLA-II-CLIP 
complex and removes CLIP. It is thought that HLA-DM serves as a chaperone 
protein that stabilizes HLA-II as it samples antigenic fragments (during which 
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there are multiple bindings and disassociations) until it locks-in a high-affinity 
peptide. HLA-DO is the other protein thought to also act as an intracellular 
regulator of HLA-DM. Once the HLA-II-peptide complex has locked in, HLA-
DM releases the HLA-II-peptide complex, and the resulting HLA-II-peptide 
complexes move to the cell surface.  
Naïve T Cell Activation 
 When DC HLA-II complex display epitopes of I/II in their ligand groove, 
this can be recognized by CD4+ T cells in the IFR. As mentioned previously, 
TLRs express cytoplasmic Toll/interleukin (IL)-1R homology domains, and these 
regions stimulate DCs to secrete cytokines needed prior to and during HLA-II-
peptide-TCR interactions (Wang et al., 2008). Activated DCs also increase 
expression of co-receptors on their surface, including class II, CD80 and CD86, 
the latter which bind CD28 on the T cell. Differentiation into T helper (Th) cells, 
such as Th1 or Th2, is dependent on the pathogen in question, and most Th1 
responses come on the heels of viral or intracellular bacterial infection, which 
would exclude S. mutans. Thus, I/II epitopes with their costimulatory molecules 
and signals induce predominantly Th2 differentiation and stimulation. IL-4 
secretion induces the expression of GATA-3, generally known as the Th2 master 
regulator (Fazilleau et al., 2009). This master regulator inhibits Th1 production 
and is essential for Th2 differentiation. Once the naïve T cells have committed to 
the Th2 path, they proliferate via Stat6 (activated by IL-4-IL-4R interactions) 
transduction pathways that are regulated by GATA-3. IL-2 also promotes naïve T 
cell activation through Stat5a. Once differentiated and activated, Th2 cells 
proliferate and respond to I/II epitopes by producing IL-4, IL-5, IL-13, and IL-25 
in the PP follicle in order to activate B cells. One interesting point is that IL-10, 
either by itself or in combination with IL-4, inhibits Th1 activation, but IL-10 is 
also implicated in IgA switching. 
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B cell Induction, Proliferation, and Class Switch Recombination 
 Similar to DCs, resting B cells in PPs also uptake I/II and are able to 
present I/II epitopes to T cells, however, in this case they present HLA-II-I/II 
complexes to activated Th2 cells, which once bound to the TCR, induces CD154 
expression on these T cells (Rodriguez-Pinto, 2005). This can generate cytokine 
signals directly secreted across the Th2-B cell synapse producing B cell migration 
into the germinal center of the follicle, proliferation, somatic hypermutation, and 
isotype switching or class switch recombination (CSR). All of these inductions 
occur because of T cell recognition of the HLA-II-I/II complex. The mechanism of 
somatic hypermutation remains unexplained, but mutations rapidly occur in 
heavy and light chains of the variable (V)-regions of Ig gene segments within the 
germinal center, ultimately leading to high affinity binding antibodies. The 
constant (C)-region genes of the B-cell Ig continue to change and mature during 
the adaptive immune response to I/II. This region is ultimately vital in recruiting 
help from other cells, and it confers functionally distinct properties to each 
isotype. Portions of the C-region of different isotypes are recognized by certain 
immune effector cells. The C-region also aids in transporting antibodies across 
barriers that would typically involve active transport, such as is the case with 
SIgA. During rapid B cell proliferation in the GC, the antibody C-region is 
modified, that while conserved in a general sense has now changed its 
functionality (i.e., CSR). CSR occurs in response to Th-produced cytokines (for 
CSR leading to IgA, the predominant cytokine is transforming growth factor 
(TGF)β with contributions from IL-2, IL-4, IL-5, IL-6, and IL-10) , which have 
been induced by HLA-II-I/II B cell-Th2 interactions in this case.  
The gene segments responsible for the various isotypes are: Cµ (IgM), Cδ 
(IgD), Cγ (IgG), Cε (IgE),  & Cα (IgA). Switching to other isotypes requires 
interacting with antigen, which in this case is controlled by HLA-II-I/II 
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recognition and induction. This mechanism is guided by switch regions in the 
DNA, stretches of intronic repetitive elements made up of approximately 150 
repeats of the GAGCT and GGGGGT sequences. In the case of IgA, these introns 
lie between the V-region exon and the µ gene and, in this case, 5’ to the α gene. 
The switch regions are named: Sμ, Sγ, Sε, & Sα.  
When the activated B-cell expressing IgM and IgD, reactive with I/II, 
receives a switch signal to express IgA, whose limiting player is that of the HLA-
II-I/II complex, the Sα and Sµ regions undergo recombination and every coding 
region between these 2 regions is deleted, thus enabling the normal DNA 
machinery to transcribe the heavy-chain transcript of IgA. Since switch 
sequences lie within introns, they will not cause frameshift mutations and thus 
functional proteins will be encoded, which once ferried to the effector sites, can 
ultimately be secreted in order to neutralize S. mutans in the oral microbiome. 
Homing to Effector Sites 
 GC IgA+ plasmablasts home to the salivary glands by traversing the 
afferent lymphatics where they course through the mesenteric lymph nodes 
(MLNs) (or the draining lymphatics), a location that also produces DC-Th2-B cell 
interactions and more effector cells, all of which find their way superiorally 
through the thoracic duct and enter the vasculature at the thoracic duct and 
subclavian vein junction. The B-cell homing system works by particular 
endothelial signals of HEVs in the various mucosal immune compartments, such 
as NALT, which includes the pharyngeal tonsil, the palatine tonsils, and the 
lingual tonsils. IgA plasmablasts programmed to play major roles in the oral 
microbiome express CCR10, which binds to the salivary gland ligand CCL28, as 
well as the α4β1 integrin, which is attracted to VCAM-1 (vascular cell-adhesion 
molecule-1) (Macpherson et al., 2008). Thus, IgA-secreting cells find their way to 
the salivary glands and the oral cavity because of the mucosal immune response 
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to S. mutans, which fundamentally revolves around HLA-II-I/II complexes, and 
sets in motion long-term protective immunity. Although the traditional journey 
of adaptive mucosal immune cells, especially IgA+ B-cells (in response to I/II 
epitopes), has been described as induction in GALT (specifically PPs) and 
effector migration to the oral microbiome, there is substantial evidence that 
NALT “may be relatively more important than GALT as inductive sites for B 
cells destined to the salivary glands” (Brandtzaeg, 2007). This fact does not 
change any of the biologically essential mechanisms thus discussed, but instead 
provides perspective on other important inductive sites against 
immunodominant epitopes of cariogenic bacteria within the oral microbiome.  
NALT is an Important Mucosal Inductive Site 
 It has become clearer that NALT functions in very similar ways as does 
GALT. One set of authors state the case clearly: 
 NALT consists of follicle-associated epithelium (FAE), HEVs, and 
T-cell- and B-cell-enriched areas. Antigen-sampling M cells are 
present in the epithelium of NALT, which is specialized for antigen 
uptake . . . Antigen-presenting cells, including dendritic cells (DCs) 
and macrophages, are also found in NALT. So, NALT contains all 
of the lymphoid cells that are required for the induction and 
regulation of mucosal immune responses to antigens (Kiyono and 
Fukuyama, 2004). 
            
Other authors point out that NALT is also very significant in generating memory 
B cells, thus arming the oral microbiome with high-affinity IgA (Jang et al., 2004) 
against I/II and other S. mutans antigens. It is also clear that NALT elicits regional 
or compartmental SIgA immunity (through cervical lymph nodes instead of 
mesenteric lymph nodes) (Brandtzaeg et al., 2008; Brandtzaeg, 2009). Finally, it is 
important to note that the mucosal immune system is much more 
compartmentalized or regionalized then has been traditionally accepted, and the 
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idea of a “common” system is now “obsolete,” as explained by one set of 
authors:  
It is important to be aware of the extensive regionalization and 
compartmentalization that exist within the mucosal immune 
system. Thus, in contrast to extravasation events in the intestine, 
α4β7 and MAdCAM-1 are not important homing molecules in the 
airways, where CD62L, α4β1, CCR7, and CCR10 appear to play a 
more decisive role (Macpherson et al., 2008).   
 
One of the foremost experts in SIgA, who has studied this antibody for more 
than 4 decades, observes “that intestinal immune induction is not so well 
reflected in the salivary IgA system” and that “the enteric–oral B cell homing 
axis” is probably overestimated (Brandtzaeg, 2007). A conservative estimate 
might anticipate that 60 percent of total SIgA activity in the oral microbiome is 
locally induced (by NALT) while 40 percent may be GALT-induced (one could 
even imagine a 70/30 split). Brandtzaeg has also been recognized for his work, 
which is now widely accepted as the model for SIgA epithelial transport 
(Macpherson et al., 2008), which we will now discuss. 
Secretory Epithelial Transport in Oral Microbiome 
 Secretory epithelial transport of SIgA in the oral microbiome happens in 
both the intercalated regions of major salivary glands as well as across serous-
type acini (Brandtzaeg, 2007). It is interesting to note that IgA-plasmablasts do 
not fully differentiate to IgA-PCs until they arrive in the LP or stroma of the oral 
glandular compartments. Taken together, the submandibular and labial glands 
contain two and three times more IgA+ PCs than the parotid gland. Moreover, 
we currently know that submandibular glands substantially exceed the parotid 
glands SIgA output. SIgA is transported with the help of a transmembrane 
epithelial receptor, pIgR (polymeric Ig receptor), previously known as membrane 
secretory component (mSC) (Brandtzaeg et al., 2008; Brandtzaeg, 2009). This 
 43 
 
receptor facilitates pIgA (Polymeric IgA; refers mainly to dimers but also 
includes larger polymers of J-chain-containing IgA) transcytosis. PCs initiate 
pIgA formation via Joining (J)-chain ligation. The J-chain polymerizes IgA and 
creates a binding site for pIgR (Braathen et al., 2007). Once bound, SIgA is 
transported apically by cleavage of the pIgR. Thus, SIgA is released into the 
salivary glandular compartments that together comprise the oral microbiome 
biofilm where SIgA can neutralize S. mutans by high affinity I/II-SIgA binding.  
Summary   
 The proposed hypothesis is therefore informed by the fact that the 
predominant effector antibody in mucosal immunity, SIgA, specifically targets 
immunodominant epitopes of S. mutans, and the predominant rate limiting step 
in this immune response fundamentally revolves around HLA-II structural genes 
and their molecules as has been discussed. Specifically, the central hypothesis is 
that there is an association between certain HLA-II allelic variants (which differ 
slightly at the structural gene level), specifically within HLA-DRB1*04, and 
inefficient HLA-DRB1*04-I/II peptide presentation to Th2 cells, thus eliminating 
in large measure, the SIgA response to S. mutans. In an HLA-I example, one 
study has demonstrated that structural gene variants do indeed yield variant 
binding grooves and a concomitant differential in affinity for particular epitopes. 
For example, HLA-B*4405, which presents an Epstein Barr Virus (EBV) epitope 
to its cognate TCR, exhibits a 10-fold increase in affinity when compared with 
HLA-B*4403 and HLA-B*4402, all of which differ by only one amino acid. Thus, 3 
studies (1 laboratory and 2 clinical) were conducted to explore and test this 
hypothesis. While the two clinical studies sought to test the overall hypothesis in 
relation to HLA-II allelic variants and SIgA, the laboratory study served as a 
precursor to the latter two in that we sought to identify epitopes of I/II that had 
already been shown to induce adaptive effector responses in humans as opposed 
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to animal models. After identifying these immunodominant regions, I/II epitopes 
were synthesized and tested with human pooled saliva to explore which of these 
epitopes might play more predominant roles in the SIgA system. The materials 
and methods used to conduct these studies as well as their results will be 
discussed in the following two chapters.  
Before that, it is important to discuss a link between a disease that 
produces salivary impairment and consistently creates an abnormally high 
nutrient-rich environment that S. mutans and other cariogenic pathogens can take 
advantage of. This disease is type 1 diabetes (T1D), and its connection to caries is 
partly explained by higher basal levels of cariogenic threat with concomitantly 
lower overall SIgA activity. At-risk T1D subjects are recruited in our third study, 
but the T1D-caries connection could not be tested in that study although this 
connection appears to be very important and future studies could be directed at 
testing its many potential hypotheses.    
The Caries and Type 1 Diabetes Connection 
The link between diabetes and a variety of oral diseases has received 
increasing attention (Hampton, 2008; Lamster et al., 2008). Some of the major oral 
diseases or disorders associated with diabetes include caries, periodontal disease, 
salivary gland dysfunction, fungal infections (e.g., oral candidiasis), lichen 
planus and other lichenoid reactions, and infection. Whether HLA-II gene 
inheritance plays a role in the increased caries increments associated with type 1 
diabetes mellitus (T1D) has not been tested, but could be a contributing factor. 
Nonetheless, a link between caries and T1D exists.  
Diabetes Mellitus has been associated with caries (Bakhshandeh et al., 
2008). Although previous data between type 1 diabetes mellitus (T1D) and caries 
is uneven, the link has been supported and recently bolstered. Previous studies 
have suggested, for example, that T1D patients exhibit more “initial buccal 
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caries” compared to controls (Edblad et al., 2001). One reason diabetes may be 
linked to caries has to do with salivary dysfunction, a risk factor for caries and a 
condition caused by, among other systemic diseases, diabetes. In fact, xerostomia 
and salivary hypofunction are important risk factors in caries, and caries is very 
difficult to prevent under these conditions (Kidd et al., 2008). Thus, T1D patients’ 
salivary secretion was greatly impaired (resting and stimulated) compared to 
controls in a matching study (Mata et al., 2004). Salivary flow is also important. 
Low resting salivary flow rate, a significant salivary parameter favoring caries 
because of impaired bacterial clearance, is observed in T1D subjects (Moreira et 
al., 2009). Thus, high caries experience in T1D patients is significantly associated 
with decreased resting salivary flow rate (Siudikiene et al., 2006).  
Moreover, relatively high levels of salivary glucose coming from both the 
serum (via gingival crevicular fluid) and the saliva (via salivary glands), foster an 
environment in which cariogenic bacteria may flourish in creating the deleterious 
dental biofilm (interchangeably called the dental plaque) and producing caries. 
Thus, salivary glucose concentration (in either resting or stimulated saliva) has 
been found to be much higher in T1D patients than in control subjects (Jurysta et 
al., 2009), and high caries experience has been correlated with the cariogenicity of 
the dental plaque (Siudikiene et al., 2006). Decayed/missing/filled surface 
(DMFS), one measure of caries experience, was recently used in assessing the 
connection between diabetes and caries. The authors found that T1D patients’ 
“DMFS increments” over a 2-year period “were associated with greater 
increments in salivary glucose concentrations” (Siudikiene et al., 2008). 
Moreover, T1D subjects exhibited increased increments of “dental plaque,” a 
necessary prerequisite in caries, and concomitantly associated “higher 
increments in active caries lesions” compared to controls. Thus, the authors 
conclude that “diabetes-induced changes in salivary glucose” foster “caries 
 46 
 
development” among T1D patients. The magnitude of this association may also 
depend on how well controlled T1D is. For example, blood glucose and 
glycosylated haemoglobin (HbAlc) data demonstrate that poorly controlled T1D 
patients, compared to well controlled T1D counterparts, produce increased 
resting salivary glucose levels, and a significantly higher caries incidence 
(Twetman et al., 2002; Twetman et al., 2005). Thus, HLA gene expression, high 
salivary glucose and low salivary flow rates may contribute to caries 
development in T1D.  
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CHAPTER THREE 
Materials and Methods 
Study #1: Human Salivary IgA Reactivity for Selected I/II Peptides 
General Description of Design  
As previously mentioned, 3 studies (1 laboratory and 2 clinical) were 
conducted to explore and test the previously described hypothesis. The materials 
and methods used to conduct these studies as well as their results will be 
discussed in this and the next chapter. 
We selected I/II peptides, obtained deidentified human saliva per 
Institutional Review Board (IRB) approval (#0304-58), and used a modified 
enzyme-linked immunosorbent assay (ELISA) (Gregory, 2001) to determine 
human salivary IgA reactivity for the peptides. We also determined which of the 
selected peptide(s) were more immunoreactive.  
Selecting, Synthesizing, and Storing I/II Peptides 
We selected I/II peptides that induce immune responses in humans, as 
opposed to animal models, by searching for articles between 1990 and 2008 that 
directly related to I/II (Web of Science search parameters: Topic=((I/II) AND 
(streptococcus mutans) AND (epitope)). With additional searches (Kelly et al., 
1995; Senpuku et al., 2007), we selected the following peptides: 
NAKATYEAALKQYEADLAAVKKANAA (361-386), 
IETGKKPNIWYSLNGKIRAV (803-822), VPKVTKEKPTPPVKPTAPTK (824-843), 
PPVKPTAPTKPTYETEKPLK (834-853), ETEKPLEPAPVEPSYEAEPT (925-944), 
PTVHFHYFKLAVQPQVNKEI (985-1004), RNNNDINIDRTLVAKQSVVK (1005-
1024), FQLKTADLPAGRDETTSFVL (1025-1044), TLATFNADLTKSVATIYPTV 
(1085-1104), KSVATIYPTVVGGVLNDGAT (1095-1114). Each peptide was 
synthesized (Peptide 2.0, Chantilly, Virginia) and lyophilized at the following 
purities (following the same order as above, in percent): 91.1, 92.2, 96.9, 98.0, 95.1, 
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96.6, 93.6, 80.6, 79.4, and 93.2. Each peptide was dissolved in distilled water to 
yield a 1mg mL-1 stock solution, which was pipetted into centrifuge tubes in 1.0 
mL aliquots and stored at -20°C.      
Human Saliva Collection and Storage 
We obtained 3 separate unstimulated human saliva samples, which we 
could not trace back to any particular subject. After combining and vortexing the 
pooled sample, saliva was pipetted into 4 centrifuge tubes in 1.5 mL aliquots and 
stored at -20°C.  
Enzyme-Linked Immunosorbent Assay 
Using ELISA, we measured human salivary IgA binding to I/II peptides. 
Each peptide stock solution was assayed at two concentrations (10 µg mL-1 and 
100 µg mL-1). To prepare the appropriate peptide concentration, the appropriate 
volume of peptide stock solution was pipetted into the appropriate volume of 
carbonate buffer (CB) at a pH of 9.6, thus producing the I/II dilution. 100µL of the 
I/II dilution was pipetted into each predetermined experimental well in the 
ELISA plate (Fisher Scientific, Hanover Park, Illinois), incubated for 3 hours at 
37°C, and refrigerated overnight at 4°C.  
The next day, a 5 percent (weight/volume) skim milk CB dilution was 
prepared. Plates were washed 3 times (3X) in Tween Saline (TS), and each 
experimental well was treated for 1 hour at room temperature with 200 µL of the 
skim milk blocking agent (preventing unbound sites from later being bound by 
antibody). During the skim milk blocking treatment, serially diluted saliva 
samples at dilutions of 1:5, 1:10, and 1:20 were prepared in TS. Once the skim 
milk incubation terminated, plates were washed 3X in TS, and 100 µL of each 
saliva dilution was added to the corresponding predetermined wells. Saliva 
dilutions containing human salivary IgA were incubated at 37°C for 1 hour. In 
the meantime, we prepared a Horse Radish Peroxidase (HRP)-Anti-human IgA 
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conjugate from goat (HRP-Anti-IgA; Sigma-Aldrich, St. Louis, Missouri) TS 
dilution (Anti-IgA) of 1:500. Once the incubation period had ended, plates were 
washed in TS 3X, and incubated for 1 hour at 4°C after adding 100 µL of Anti-
IgA to each well. 
Salivary IgA antibodies which bound I/II peptides were determined by the 
combination of Anti-IgA incubation at 37°C for 1 hour and subsequent reaction 
with o-Phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich, St. Louis, 
Missouri) in CB (with 30% H2O2). Control wells (no saliva) were only subjected to 
TS, Anti-IgA, and OPD, respectively. After 35 minutes of color development, and 
quenching of the reaction by pipeting 100 µL of 2N H2SO4 into each well, the 
absorbance of each well in the plates were read at 490 nm with the SpectraMax 
190 (Molecular Devices, Sunnyvale, California). 
Data Analysis 
 All experiments were done in triplicate and are reported as means and 
standard errors of the mean.  
Study #2: HLA-II Gene Association with SIgA in the Caries Process 
Study Design 
This clinical study was carried out per IUPUI/Clarian IRB approval (# 
0811-50). We collected saliva from 15 subjects with known caries scores. These 
scores were previously determined using the International Caries Detection and 
Assessment System or ICDAS, and could be used for this study because subjects 
had had ICDAS exams done 1-2 years prior to this project by trained and 
calibrated  examiners. Each subject provided two saliva samples, one for 
bacterial and antibody analysis (1 mL analyzed the same day, and 1-2 mL stored 
frozen at -20°C), and the other for genetic analysis (3 mL stored at room 
temperature). Chi square tests were used to determine the association between 
HLA-DRB1*04 (an HLA-II allele), and levels of mutans streptococci, salivary IgA 
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activity, and caries. Salivary IgA was the primary outcome, while bacterial and 
caries outcomes were secondary (n=15). 
Study Population 
Subjects who had previously indicated interest in research at the Oral 
Health Research Institute, and had received an ICDAS exam within the last 1-2 
years by a calibrated ICDAS examiner, were recruited. A Caucasian population 
was recruited as previous literature suggested an association between the 
biomarker being studied and caries in this population. Those who participated 
were remunerated $25.  
Inclusion Criteria:  
1. Willing to provide written informed consent and authorization for 
release of health information for research. For children 12-17, an assent 
was also obtained along with parent/legal guardian consent  
2. Age must be between 12 and 35 years of age  
3. Have on file records demonstrating either an ICDAS score of less than 3 
(ICDAS = 0, 1, & 2) indicating a less severe caries state, or have 5 or more 
lesions with an ICDAS score greater than or equal to 3 (ICDAS = 3, 4, 5, & 
6) indicating a more severe caries state.  
4. Be White non-Hispanic. 
5. Willing to attend one study visit and provide 2 saliva samples.   
Exclusion Criteria:  
1. Those that do not meet the inclusion criteria.       
Clinical Study Procedures 
Subjects fitting the inclusion criteria were contacted by phone and invited 
to participate. Those who participated were remunerated $25. At the study visit, 
after completing the informed consent process, subjects were asked to provide 
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their medical history, demographic information, and to answer questions 
regarding the inclusion or exclusion criteria.  
Human Saliva Collection and Storage 
For the first sample, unstimulated saliva was collected as subjects were 
instructed to provide at least 2 mL of saliva into a 50 mL sterile tube. After the 
samples had been transferred to the laboratory and vortexed, 1 mL was pipetted 
out into a separate, smaller centrifuge tube, stored on ice and processed the same 
day for bacterial analysis. The rest of the sample was divided into 1 mL aliquots 
and stored at -20°C to later use for salivary IgA analysis.  
The second sample required approximately 3 mL of stimulated saliva 
(stimulated for 2 min by chewing on paraffin), which was expectorated into 
Oragene® DNA sample collection kits (DNA Genotek, Kanata, Ontario, Canada), 
and stored at room temperature for HLA DNA genotyping. 
HLA Genotyping 
Manual Purification of DNA from 0.5 mL of Oragene®•DNA/saliva 
From the saliva samples that had been stored in Oragene® DNA sample 
collection kits (DNA Genotek, Kanata, Ontario, Canada) for HLA genotyping, 
the DNA was purified exactly as published in the above-named laboratory 
protocol (see 
http://www.dnagenotek.com/DNA_Genotek_Industry_AR_SCA_P.html) with 
the following exceptions. No glycogen was added in order to make the initial 
pellet more visible. We did, however, add an ethanol wash step in order to 
facilitate the abatement of any residual DNA inhibitors from the DNA pellet.  
After adding buffer to the DNA pellet, we added another step to ensure 
complete hydration of the DNA by vigorously pipetting and vortexing the 
sample. This was important since incomplete hydration causes inaccurate 
calculations of DNA concentration, and could interfere with our downstream 
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application. We quantified the DNA by absorbance according to the protocol. It 
is important to note that gloves were worn when pipetting, touching, or working 
in any way with the microcentrifuge tubes in order to prevent oils or other 
human DNA from contaminating the tubes or pipets.  
We determined group-speciﬁc HLA-DRB1 alleles using HLA-DRB-speciﬁc 
ﬂuorogenic probes, and employing polymerase chain reaction (PCR) using the 
LightCycler ® 480 Real-Time PCR System (Roche Applied Science, Indianapolis, 
Indiana). As controls, we used 3 cell lines (courtesy of Dr. Janice S. Blum) that 
were known to be homozygous for HLA-DRB1*0401 (Priess), heterozygous for 
HLA-DRB1*04 (Frev; also known for HLA-DRB1*01), or negative for HLA-
DRB1*04 (Sweig; homozygous for HLA-DRB1*1101).   
Accordingly, DRB1*04 exon primers were tailed with M13f–21 forward 
and M13 reverse sequences, respectively (Danzer et al., 2007). The amplification 
reactions were carried out in a final volume of 10 µL using the following master 
mixture: 5 µL of FastStart DNA Master Hybridization Probes mix (Roche 
Diagnostics); 1 µL of TaqMan probe; 1 µL of forward primer (M13f-21 Forward, 
5’- GTA AAA CGA CGG CCA G -3’; Integrated DNA Technologies, Coralville, 
Iowa); 1 µL of the reverse primer (M13 Reverse, 5’- CAG GAA ACA GCT ATG 
AC -3’); and 1 µL of PCR Boost (Applied Biosystems), all of which had final 
concentrations of 200 nmol/L except for the PCR Boost, which we know 
minimizes water from the sample but whose formulation is proprietary. All 
primer oligonucleotides were synthesized by Integrated DNA Technologies. 
Quantification of how many ng/µL of DNA had been isolated for each sample 
was determined by pipetting 1 µL of sample onto the lower measurement 
pedestal of the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, Delaware), closing the sampling arm, and beginning measurement 
using the coupled operating software (after blanking the instrument by adding 
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the same concentration of carrier liquid). The DNA concentration of 10 ng/µL for 
each sample was achieved by adding the appropriate amount of water to each 
sample. Once the 9 µL of master mix was prepared and pipetted into a 1.5 mL 
centrifuge tubes, 1 µL of each DNA sample (at 10 ng/µL) was added. The 
following procedure was then used:    
The LightCycler program consisted of an initial denaturation 
for 10 minutes at 95°C followed by 10 cycles of 95°C for 5 seconds, 
65°C for 20 seconds, and 25 cycles of 95°C for 5 seconds, 60°C for 20 
seconds. In case of PCRs with intron primers, extension time was 
increased to 60 seconds. The PCR products were analyzed by 
Absolute Quantification selection in channel [465–510] nm 
(LightCycler 480). After evaluation for the presence or absence of a 
fluorescence signal from the group-specific PCR using the software 
readout, a 5 µL quantity of the PCR products was treated with 2 µL 
of ExoSAP-IT (Applied Biosystems) to remove primers and dNTPs, 
according to the manufacturer’s instructions. Direct cycle 
sequencing was performed in a 9800 Fast Thermal Cycler (Applied 
Biosystems) in 10 µL of reaction volume containing 1 µL BigDye v 
3.0 (Applied Biosystems), 1 µL sequencing buffer, and 400 nmol/l of 
the respective sequencing primer (M13rev; M12f–21)” (Danzer et 
al., 2007). 
 
Bacterial Analysis 
Whole saliva was diluted 1:10, 1:100 and 1: 1,000, double-plated on Mitis 
Salivarius agar supplemented with bacitracin and sucrose (MSSB) (Anaerobe 
Systems, Morgan Hill, California). The plates were incubated for 48 hours at 
37°C, 5 percent CO2, and subsequently the number of S. mutans colonies 
enumerated using Protocol (Synoptic LTD, North Cambridge, United Kingdom), 
thus yielding S. mutans colony-forming units mL-1 (CFU mL-1).   
Enzyme-Linked Immunosorbent Assay 
Using ELISA, we measured human salivary IgA binding to I/II peptides. 
Each peptide stock solution was assayed at 10 µg mL-1. To prepare the 
 54 
 
appropriate peptide concentration, the appropriate volume of peptide stock 
solution was pipetted into the appropriate volume of CB at a pH of 9.6, thus 
producing the I/II dilution. 100µL of the I/II dilution was then pipetted into each 
predetermined experimental well in the ELISA plate (Fisher Scientific, Hanover 
Park, Illinois), incubated for 3 hours at 37°C, and refrigerated overnight at 4°C.  
The next day, a 5 percent (weight/volume) skim milk CB dilution was 
prepared. Plates were then washed 3X in TS, and each experimental well was 
treated for 1 hour at room temperature with 200 µL of the skim milk blocking 
agent (preventing unbound sites from later being bound by antibody). During 
the skim milk blocking treatment, serially diluted saliva samples at dilutions of 
1:5 and 1:10 were prepared. Once the skim milk incubation terminated, plates 
were washed 3X in TS, and 100 µL of each saliva dilution was added to the 
corresponding predetermined wells. Saliva dilutions containing human salivary 
IgA were incubated at 37°C for 1 hour. In the meantime, we prepared a HRP-
Anti-IgA (Sigma-Aldrich, St. Louis, Missouri) TS dilution (Anti-IgA) of 1:500. 
Once the incubation period had ended, plates were washed in TS 3X, and 
incubated for 1 hour at 4°C after adding 100 µL of Anti-IgA to each well.  
Salivary IgA antibodies which bound I/II peptides were determined by the 
combination of Anti-IgA incubation at 37°C for 1 hour and subsequent reaction 
with SIGMAFAST™ OPD (Sigma-Aldrich, St. Louis, Missouri). The ELISA plates 
were washed in TS 3X to discard unbound constituents. 100 µL of the OPD 
solution was pipetted into each well. After 15 minutes, the reaction was 
quenched by pipeting 100 µL in each well of 2N H2S04, and the plates were read 
on the SpectraMax 190 (Molecular Devices, Sunnyvale, California) at 490 nm. 
Negative control wells (no saliva) were only subjected to TS, Anti-IgA, and OPD, 
respectively. These controls expressed any background noise, and this noise was 
subtracted after correcting raw data values. Interplate positive reference controls 
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(of human pooled saliva samples) were incubated with the I/II peptide, 1085-
1104, and were subjected to the same procedures as all other sample wells. These 
controls allowed any interplate variability to be factored out of the analyses.    
Data Analysis 
 All experiments were done in either duplicate or triplicate and are 
reported as means and standard errors of the mean. Differences (between HLA-
DRB1*04 positive and negative groups as well as between high caries and low 
caries groups) in salivary IgA reactivity were determined using a chi square test 
or a student’s t-test. ICDAS data were correlated with bacterial and salivary IgA 
data from those subjects for whom we had bacterial levels.    
Study #3: HLA-II gene Influence in Caries Experience in an at-risk type 1 
diabetes population on Salivary IgA Response. 
Study Design 
The study population was divided into two groups: an *04 NEGATIVE 
group (n=16) and an *04 POSITIVE group (n=16). After completing the informed 
consent process, subjects were asked to provide medical history and 
demographic information and to answer questions regarding the 
inclusion/exclusion criteria. Each subject received a clinical exam by a trained 
and calibrated examiner with regard to caries experience using ICDAS II, a novel 
yet validated and robust approach to detect and assess caries (Jablonski-Momeni 
et al., 2008; Rodrigues et al., 2008). Kappa values for intra-examiner 
reproducibility for the ICDAS-II examination were 0.68 (from a long term clinical 
trial), and 0.89 from a similar study during training with the gold standards of 
Drs. Ekstrand and Nyvaad. A recent 18 month follow-up study was reported by 
Prof. Eckert with a repeatability weighted kappa of 0.77. At the time of the 
subject’s visit, 5-6 mL of unstimulated whole saliva was collected from both 
groups of subjects and stored at either -80°C or -20°C until laboratory analysis. 
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Bacterial numbers (mutans streptococci) were evaluated per mL of whole saliva. 
Levels of salivary IgA antibodies to I/II epitopes of S. mutans UA159, and whole 
cells of S. mutans (UA159, NG8 and PC3370) were detected using ELISA. Subjects 
did not brush their teeth at least a few hours before they participated in the study 
although this was not formally required, but verified post-hoc. Even if someone 
had done so, only bacterial data would have been compromised while SIgA data 
would remain unaffected. Differences between DRB1*04 positive and negative 
groups were examined using a two-sided, two-sample t-test. 
Sample Size Calculation  
A sample size of 17 subjects each from DRB1*04 positive and negative 
group (totaling 34 subjects) would have 80% power to detect a 1.0 standard 
deviation difference between the two groups, assuming a two-sided two-sample 
t-test and a 5% significance level. A literature review and preliminary data from 
the second clinical study demonstrated a mean (SD) for salivary IgA mg 100 mL-1 
of 2.0 (0.5) for DRB1*04 positive subjects. The variability in the proposed study 
was assumed to be similar, thereby predicting an ability to detect a 25% 
difference in salivary IgA between the DRB1*04 positive and negative subjects.  
Study Population  
The predominant number of healthy subjects in this study were recruited 
from the TrialNet Natural History Study (TN NHS), where we recruited healthy 
yet at-risk for T1D subjects. Subjects who are DRB1*04 positive (as indicated 
from Phase 2 or 3 participation of TN NHS, or as indicated by a saliva test at the 
time of study visit) were invited to participate. Matched sex, race and age control 
subjects (see table 3) testing negative for DRB1*04 were also invited to 
participate. Those who participated were remunerated $50.  
 
Inclusion Criteria:  
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1. Willing to provide written informed consent and 
authorization for release of health information for research. For 
children 6-17, an assent needed to be obtained along with 
parent/legal guardian consent.  
2. Age must be matched in both the experimental and control 
groups. 
3. Ethnicity must be matched (The IU TN NHS is an all 
Caucasian population and thus our sample was a Caucasian 
population; the literature suggests significant HLA differences 
among distinct populations, see (Ozawa et al., 2001)).   
4. Sex must be matched. 
5. Other pertinent demographic variables should be matched. 
6. Willing to attend one study visit and provide 1 saliva 
sample.   
Exclusion Criteria:  
1. Those that do not meet the inclusion criteria. 
Clinical Procedures  
At the study visit, the subject or parent completed a subject’s informed 
consent form and an authorization for the release of health information for 
research form.  Children under 18 were given a similar letter of assent. The 
information presented to the subject and parent was explained during the 
Informed Consent Process and the subject and parent had an opportunity to ask 
questions and decide if they wished themselves or their child to participate in the 
study. Upon the subject’s/parent’s signing of the consent/assent forms, the 
subject’s medical history and the inclusion/exclusion criteria were reviewed. The 
subjects accepted into the study received an oral soft tissue exam.  
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In some cases, 2 samples of saliva were collected. In the case where DNA 
had already been collected, and only one saliva sample was required, that 
sample was collected and later divided in the laboratory into 2 samples, one for 
bacterial analyses and the other for antibody analyses. Subjects were instructed 
to provide at least 5 mL of unstimulated saliva into a 50 mL sterile tube and 
timed in order to calculate a salivary flow rate. After the samples had been 
transferred to the laboratory and vortexed, 0.9 mL was pipetted out into a 
separate, smaller centrifuge tube and mixed with 0.2 mL of glycerin for each 
sample, vortexed again and then stored at -80°C until bacterial analysis. The rest 
of the sample was then divided into 1.5 mL aliquots and stored at -20°C so as to 
prevent unnecessary freeze/thaw cycles and allow repeat assays if needed.  
In those cases requiring 2 saliva samples, the first sample included the one 
previously discussed, and the second sample was collected for DNA purposes 
(to determine if the participant was HLA-DRB1*04 positive or negative). This 
sample requires approximately 3 mL of stimulated saliva (stimulated for 2 min 
by chewing on paraffin). This DNA sample was only collected from participants 
for whom we did not have HLA typing data, and stored in Oragene® DNA 
sample collection kits (DNA Genotek, Kanata, Ontario, Canada) at room 
temperature. Following the saliva collection, subjects had their teeth brushed by 
study personnel. They then received an ICDAS exam by one calibrated examiner. 
Upon completion of the ICDAS exam, the subject’s participation ended. 
ICDAS-II Examination  
The examiner performed a visual caries examination of all teeth in the 
dentition using the ICDAS-II criteria. Anterior teeth must have been fully 
erupted to be examined, while posterior teeth were examined if the full occlusal 
surface was visible. In the case of missing permanent teeth, the examiner 
attempted to establish the cause. This examination will be performed using 
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conventional dental equipment including dental chairs and lights, compressed 
air and plane surface mirrors. The criteria used in the ICDAS-II diagnostic 
system are as follows: 
Tooth codes   
S  = sound 
U = unerupted 
X = extracted, presumed for the reasons of caries 
Y = extracted for other reasons, e.g. orthodontic reasons 
N = not gradable, e.g. for reasons of trauma 
C = caries or caries related events such as fillings 
0 = Sound tooth surface.  
1 = First visual change in enamel.  
2 = Distinct visual change in enamel.  
3 = Localized enamel breakdown due to caries with no visible dentin.  
4 = Underlying dark shadow from dentin +/- localized enamel breakdown.  
5 = Distinct cavity with visible dentin.  
6 = Extensive distinct cavity with visible dentin.  
In addition, the activity of the caries lesions detected was determined, in 
accordance with the ICDAS-II recommendation:  
 1 = Not active  
 2 = Active lesion 
Fillings: 
1 = Sealant, partial 
2 = Sealant, full 
3 = Tooth colored restoration 
4 = Amalgam restoration 
5 = Stainless steel crown 
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6 = Crown, gold, porcelain or MCC 
7 = Lost restoration 
8 = Temporary restoration 
9 = Other 
Genetic Analyses (HLA typing) 
Most HLA typing was already completed under the TrialNet protocols for 
phase 2 and 3 subjects in TH NHS. Any remaining procedures were 
accomplished exactly as specified on pages 51-53 of this chapter.  
Bacterial Analyses 
Aliquots of whole saliva (0.9 mL) with glycerin (0.2 mL) were stored at -
80°C until they were thawed for analysis. Each sample was diluted 1:100 and 
1:1,000 in sterile saline, double-plated on Mitis Salivarius agar supplemented 
with bacitracin and sucrose (MSSB) (Anaerobe Systems, Morgan Hill, California). 
The plates were incubated for 48 hours at 37°C, 5 percent CO2, and subsequently 
the number of S. mutans colonies enumerated using Protocol (Synoptic LTD, 
North Cambridge, United Kingdom), thus yielding S. mutans colony-forming 
units/mL (CFU/mL).   
Enzyme-Linked Immunosorbent Assay 
In preparation of individual saliva samples being used to conduct ELISA 
SIgA antibody assays to the 10 selected epitopes, optimization assays were 
completed and repeated until refined (Figs. 6-8; Table 1). There were two 
important needs regarding these assays. Absolute absorbance numbers needed 
to be in the range of 0.40 to 1.20 in optimization samples in order to provide 
additional room for those individuals who would undoubtedly respond outside 
this range so as to not compromise the results in either direction. It was observed 
during the optimization assays that one unidentified subject was a low 
responder at a secondary antibody concentration of 1:15,000 (Fig. 7). Neither the 
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pooled nor other individual samples were too low at the 1:10,000 dilution of 
secondary antibody, nor did any of the samples provide too high an absorbance 
at this dilution (Figs. 6-8), whereas two out of three samples were too high at the 
1:5,000 dilution. Additionally, it was considered important to make sure that 
both primary and secondary antibody concentrations produced TS negative 
control absorbance data that fell below 10 percent of each sample’s reactivity 
(Table 1). Only an anti-IgA detection antibody concentration of 1:10,000 and a 
saliva dilution of 1:10 fulfilled both of these requirements. 
Using ELISA, human salivary IgA binding to I/II peptides was measured. 
Each peptide stock solution was diluted to 1 µg mL-1. To prepare the appropriate 
peptide concentration, the required volume of peptide stock solution was 
pipetted into the desired volume of CB, thus producing the 1 µg mL-1 I/II epitope 
dilution. For antigen coating, 100µL of the I/II dilution was pipetted into each 
predetermined experimental well in the ELISA plate (Fisher Scientific, Hanover 
Park, Illinois), incubated for 3 hours at 37°C, and refrigerated overnight at 4°C.  
The next day, a 5 percent (weight/volume) skim milk CB dilution was 
prepared. Plates were washed 3X in TS, and each experimental well was blocked 
for 1 hour at room temperature with 200 µL of the skim milk blocking agent. 
During skim milk treatment, serially diluted saliva samples at dilutions of 1:5 
and 1:10 in TS were prepared. Once the skim milk incubation terminated, plates 
were washed 3X in TS, and 100 µL of each saliva dilution was added to 
corresponding predetermined wells. Saliva dilutions containing human salivary 
IgA were incubated at 37°C for 1 hour. In the meantime, an HRP-anti-IgA 
(Sigma-Aldrich, St. Louis, Missouri) TS dilution (anti-IgA) of 1:10,000 was 
prepared. Once the incubation period ended, plates were washed in TS 3X, and 
incubated for 1 hour at 4°C after adding 100 µL of anti-IgA to each well.  
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The relative level of salivary IgA antibodies which bound I/II peptides 
were determined by the combination of anti-IgA incubation at 37°C for 1 hour 
and subsequent reaction with SIGMAFAST™ OPD (Sigma-Aldrich, St. Louis, 
Missouri). The ELISA plates were washed in TS 3X to discard unbound 
constituents and 100 µL of the OPD solution was pipetted into each well. After 
30 minutes, the reaction was quenched by pipeting 100 µL in each well of 2N 
H2S04, and the plates were read on the SpectraMax 190 (Molecular Devices, 
Sunnyvale, California) at 490nm. Negative control wells (no saliva) were only 
subjected to TS, anti-IgA, and OPD, respectively. These controls expressed any 
background noise, and this noise was subtracted out after correcting raw data 
values. Interplate positive reference controls were incubated with the I/II 
peptide, 1085-1104, and were subjected to the same procedures as all other 
sample wells. These controls allowed any interplate variability to be factored out 
of the analyses.  
Using ELISA, human salivary IgA binding to 3 strains of S. mutans was 
also determined. Page Caufield at the University of Alabama, Birmingham, 
kindly provided the S. mutans UA159 strain to the Gregory Laboratory; it is also 
a part of the American Type Culture Collection (ATCC 700610). The UA159 
genome can be electronically accessed (access # NC_004350) (Ajdić et al., 2002). 
The other two strains, NG8, and an NG8-derived I/II-mutant strain, PC3370 
(Crowley et al., 1999), were kindly provided to the Gregory Laboratory by Dr. L. 
Jeannine Brady in the Department of Oral Biology, at the University of Florida, 
Gainesville, Florida. All three strains, UA159, NG8, and PC3370 had been stored 
at -80°C in glycerol. These cells were cultured separately in Todd-Hewitt broth 
(THB, Acumedia, Baltimore, MA) overnight in a 5% CO2 air incubator at 37°C, 
centrifuged at 8500 RPM for 20 minutes the next day until the supernatant could 
be removed, leaving the initial bacterial cell pellet. The pellet was resuspended 
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by vortexing the solid pellet in 0.15 M saline, then washed by centrifugation 
again, which was repeated twice. The pellet was resuspended a third time in 100 
mL of 0.15 M saline with 0.5 mL formaldehyde to give a 0.5% concentration. 
These cells were incubated with the formaldehyde mixture at room temperature 
for 48 hours to kill the cells. Then, the cells were washed 2X in saline in order to 
remove the formaldehyde. The cells were resuspended in sodium 
carbonate/bicarbonate buffer, and diluted until a 0.5 OD was achieved at 660 nm 
using the SpectraMax 190.  
Data Analysis 
All experiments were done in either duplicate or triplicate and are 
reported as means and standard errors of the mean. ICDAS-II data were 
correlated with lesion activity, bacterial levels, and salivary IgA data from all 43 
subjects (n=18, DRB1*04 positive; n=25, DRB1*04 negative). However, to 
minimize exogenous variables in ultimately making any conclusions, a more 
conservative, matched sample of subjects was selected from the overall sample 
(n=16 in each group; see Table 3).  
Paired t-tests were used to compare the matched pairs from the DRB1*04 
positive and negative groups. When the analyses were not restricted to matched 
pairs, two-sample t-tests were used for the comparisons. Pearson correlation 
coefficients were calculated to assess the linear relationships between variables. 
A natural logarithm transformation of the variables was used for most analyses 
due to the non-normal distribution of the data. 
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CHAPTER FOUR 
Results 
From the outset, it is important to generally qualify data hereafter 
presented. Though certain groups may appear numerically distinct from other 
groups, comparisons are not statistically significant unless explicitly stated. 
Nonetheless, this research does provide some interesting trends, especially in the 
third study, as well as suggestions that provide added information and may 
provide researchers new directions in the pursuit of understanding caries at its 
fundamental level—in rational vaccine design and searching for biomarkers that 
predict caries susceptibility.  
In the first study, at two separate dilutions, and across seven initially 
selected epitopes, one eptiope in the C-terminal domain (Fig. 1) located between 
the last proline-rich repeat in the P region (so named because of proline repeats) 
and the LPxTG anchor (1085-1104), was numerically but not statistically, more 
immunoreactive than the others (Figs. 2 and 3). These data came from a sample 
of pooled saliva (n=3), samples from subjects whose genetic makeup are 
unknown. Nonetheless, these data demonstrate that, at least in this particular 
sample, 1085-1104 is an important SIgA binding region on I/II in relation to the 
other regions studied despite the fact that these data cannot be directly 
compared. Another epitope straddling the P3 region in the P region, and the C-
terminal region (985-1004), became equally immunoreactive when the peptide 
concentration was increased by 10 fold (Fig. 3). Additionally, there is a 
dichotomous relationship between the first three peptides, 803-822 (located in the 
variable, or V region, which is also a gp340 binding site), 824-843 (straddling the 
V region on the amino-terminus side and the P region, specifically P1, at the 
carboxy-terminus, which region crosses another gp340 binding site), and 834-853 
(the same as 824-843 except that it is almost entirely located in P1 of the P region, 
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but also straddles the gp340 binding site), and the last four peptides, 925-944 (P3 
of the P region), 985-1004 (straddling P4 of the P region and the C-terminal 
domain), 1085-1104 (C-terminal domain), and 1095-1114 (C-terminal domain); in 
that the combined mean immunoreactivity (OD 490 nm) of the former group is 
0.11 ± 0.01 and 0.56 ± 0.14 for the latter (p = 0.055).  
In the second and third studies, subjects having the HLA-DRB1*04 
immunogenetic biomarker were identified using HLA-DRB-speciﬁc ﬂuorogenic 
probes, by polymerase chain reaction (PCR) using the LightCycler ® 480 Real-
Time PCR System (Fig. 4). In the second study, no correlations between higher 
caries and DRB1*04 positive subjects were observed. However, in seven out of 10 
epitopes, DRB1*04 positive subjects had numerically, but not statistically, higher 
SIgA responses than their negative counterparts (Fig. 5). DRB1*04 positive 
subjects appeared to exhibit lower levels of S. mutans although these 
observations were not statistically significant (Fig. 9).   
In the third study, reminiscent of the first laboratory study, all four 
downstream epitopes, 361-386 (straddles A2 and A3 in the A region, so named 
because of alanine repeats), 803-822, 824-843, and 834-853, located along I/II at 
the carboxy-terminus of the V region and the amino-terminus of the P region as 
previously described, induce less immunoreactivity (OD 490 nm) in both 
DRB1*04 positive and negative groups (0.76 ± 0.01) compared to the next 5 
epitopes, 925-944, 985-1004, 1005-1025, 1025-1044, and 1085-1104, all located at 
the carboxy-terminus of the P region or in the C-terminal domain as previously 
described, which induce higher reactivity in both groups (0.98 ± 0.03). This 
difference is statistically significant (p ≤ 0.004). The uppermost upstream epitope 
(1085-1104) was numerically, but not statistically, the least responsive of all 10 
epitopes assayed (0.62 ± 0.06).  DRB1*04 positive subjects (0.88 ± 0.09), compared 
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to their non-biomarker counterparts (0.79 ± 0.07), exhibited numerically, but not 
statistically, higher immunoreactivity to nine out of 10 epitopes.  
Although the third study demonstrated that DRB1*04 positive subjects 
(n=18, unpaired; n=16 paired) had numerically, but not statistically, higher 
reactivity to these epitopes, the exception was 834-853 (Figs. 11, 14, 16). This 
epitope’s amino-terminus straddles the carboxy-terminus of the V region and the 
epitope’s carboxy-terminus encompasses most of the P1 region, which appears to 
be a very important interface between all three regions when biologically 
functional in three dimensions. Although not statistically significant, DRB1*04 
positive subjects exhibited lower specific SIgA activity to 834-853 (Fig. 14) and 
also a lower reactivity ratio of 834-853/whole cell S. mutans UA159 (Fig. 16). 
Additionally, specific activity, and reactivity ratio figures exhibited the same 
dichotomous relationship (lower SIgA response versus higher SIgA response) 
between the lower downstream four epitopes, which account mainly for parts of 
the A and V regions, but also the first domain in the P region  (361-386, 803-822, 
824-843, and 834-853), and the subsequent upper 5 epitopes (925-944, 985-1004, 
1005-1025, 1025-1044, and 1085-1104; accounting for the C-terminal end of the P 
region) in both the DRB1*04 positive and negative goups. DRB1*04 positive 
subjects also exhibited numerically, but not statistically significant, higher 
specific activity SIgA responses to all three S. mutans strains assayed (Fig. 17), 
and antibody reactivity to the UA159, NG8, and PC3370 strains (Fig. 15), except 
reactivity to NG8 in both groups is at a similar level. In an indirect measure of 
immunoreactivity against the entire I/II antigen (PC3370 subtracted from the 
NG8 strain), DRB1*04 positive subjects exhibited lower responses, though not 
statistically significant, to I/II in its entirety, suggesting that when encountering 
the entire antigen, in contrast to the selected peptides, these subjects were not 
able to respond as well as their non-biomarker counterparts (Fig. 18).  
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In contrast to exhibiting higher SIgA responses to most peptides, or to 
other substrates (whole cells of UA159, NG8 and PC3370), though statistically 
insignificant, DRB1*04 positive subjects demonstrated 25-30 µg mL-1 lower total 
IgA (TIgA) than negative subjects (Fig. 13). These determinations (Table 2) were 
accomplished by creating a standard curve fit to mean data points from standard 
concentrations of human colostral IgA, including 200, 100, 50, 25, 12.5, 3.1, and 0 
µg mL-1, respectively (Fig. 12). Absorbance values were used to predict actual 
concentrations of total salivary IgA by using the standard curve equation from a 
log-log function (R2 = 0.991), and then plugging each subject’s reactivity (1:15 
saliva dilution in TS) to unlabeled, human IgA into the function, thus providing 
the correct concentration in µg mL-1. The total salivary IgA concentrations in all 
43 subjects ranged from 11.1-420.4 µg mL-1, in agreement with a very recent 
report demonstrating total salivary IgA concentrations ranging from 13.7-483.0 
µg mL-1 in 134 healthy individuals (Booth et al., 2009). DRB1*04 positive subjects 
(n=18, unpaired) had a numerically, but not statistically, lower salivary flow rate 
(0.55 ± 0.08 min-1 compared to 0.71 ± 0.10 min-1 in 25 negative subjects) (Fig. 10), 
and although this does not constitute a trend, these subjects may have a 
disadvantage of experiencing a 200 µg mL-1 salivary IgA deficit per day. When 
examining only the DRB1*04 positive subjects from the matched study (table 3; 
n=16), however, the differences in salivary flow rate disappeared making the 
groups indistinguishable with regard to this factor.     
Tables 4 and 5 suggest interesting phenomena by themselves, although 
this phenomena does not hold up when taking into account other past caries 
experience in both the DRB1*04 positive and negative groups. If we were to rely 
solely on the data from Tables 4 and 5, we may conclude that there are more 
irreversible caries lesions in the DRB1*04 positive group compared to the 
negative group. However, by analyzing the full spectrum of data available, it is 
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clear that each group cannot be distinguished from each other when taking into 
account not only irreversible ICDAS-II lesions, but also past caries experience 
(Table 6).   
Since ICDAS-II criteria represent the spectrum of caries progression, or 
the caries process, as it develops from its reversible stages to its irreversible 
development, it is thought that much can be gleaned by comparing differences 
between the reversible and irreversible processes of caries among groups. 
Unfortunately, it was impossible to control for a variety factors that may mask a 
putative negative effect the DRB1*04 biomarker may have.  
In order to normalize the distribution among ICDAS-II scores, these data 
were transformed by taking the natural log of the scores. Then, ratios which 
reflected the irreversible predisposition of caries in each group, were calculated 
and refined by taking into account the breadth of the data available (table 6). The 
mean ratios of each group were statistically compared. A higher irreversible ratio 
number indicates that the caries process is more likely to cross the threshold 
from reversible to irreversible disease. Whereas a lower value indicates that the 
caries process is likely to abate before progressing to an irreversible level. The 
two groups were indistinguishable.   
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Table 1. Optimization of Tween Saline negative control* 
Pooled Saliva, 1:10 Dilution 9.2% 5.6% 6.6% 6.6%
Pooled Saliva, 1:20 Dilution 11.6% 8.3% 9.7% 9.4%
Individual #1 Saliva, 1:10 Dilution 13.2% 7.9% 10.3% 10.7%
Individual #1 Saliva, 1:20 Dilution 18.0% 11.8% 15.6% 16.7%
Individual #2 Saliva, 1:10 Dilution 8.4% 5.4% 5.9% 5.6%
Individual #2 Saliva, 1:20 Dilution 10.8% 6.7% 8.2% 7.3%
Secondary Antibody Dilutions 1:5,000 1:10,000 1:15,000 1:20,000
Control %  of Primary Antibody ReactivityDilutions
 
*Optimization of Tween Saline (TS) negative control (control) as a percentage of 
salivary IgA immunoreactivity to one selected putative epitope of an S. mutans 
adhesin, I/II. Reactivity (1:10 and 1:20 saliva dilutions in TS) to the selected 
peptide (1085-1104; numbers reflect amino acid residues; 1 µg mL-1) was 
determined in triplicate using ELISA, on high-binding ELISA plates, and 
detected by HRP-labeled, anti-human IgA (at 4 separate dilutions: 1:5,000, 
1:10,000, 1:15,000, and 1:20,000 in TS), and subsequent reaction with OPD. The TS 
negative control solution takes the place of saliva, and its reactivity values are 
presented in this table as percentages within the table itself, calculated by taking 
the control’s reactivity, as measured by optical density absorbance (490 nm), and 
divding by the OD values observed for each of the saliva samples. Notice that in 
every case, a 1:10 dilution of saliva and a 1:10,000 secondary antibody dilution 
yields the lowest percentages within the table, including 5.6%, 7.9%, and 5.4%. 
These data are reported as contol OD percentages of each saliva sample’s OD 
values. 
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Table 2. Unpaired subjects’ raw data from the third clinical study* 
Subject # DRB1*04+ = 1 S. mutans  (CFU mL-1) Saliva Flow (mL min-1) Total IgA (µg mL-1)
1001 0 2310000 0.23 136.37
1002 1 2560000 0.31 120.57
1003 1 1140000 0.22 30.63
1004 1 1020000 0.38 68.18
1005 1 80000 0.86 48.77
1006 0 1210000 0.35 420.36
1007 0 2730000 0.35 269.98
1008 0 2350000 0.70 78.21
1009 0 6420000 1.19 32.33
1010 0 1400000 0.25 125.66
1011 0 931831 0.12 106.29
1012 1 1370000 0.28 233.72
1013 1 1820000 0.63 233.72
1014 0 3510000 0.65 269.98
1015 1 88000 0.63 48.77
1016 1 831510 0.40 41.96
1017 0 426000 0.55 65.08
1018 0 2030000 0.98 56.45
1019 0 1090000 0.53 332.75
1020 1 2420000 1.00 39.87
1021 1 564000 0.70 34.09
1022 0 1580000 0.55 153.79
1023 0 1360000 0.70 19.50
1024 0 528000 0.20 32.33
1025 0 4640000 0.51 44.14
1026 0 6640000 0.63 24.56
1027 0 1530000 1.25 29.01
1028 0 1350000 0.52 27.46
1029 0 3160000 no data 166.38
1030 1 951860 1.79 136.37
1031 0 67000 0.57 15.32
1032 0 156000 1.57 23.21
1033 1 71000 0.48 11.14
1034 1 54000 0.54 19.50
1035 0 560000 0.84 23.21
1036 1 456000 0.33 74.75
1037 0 5700000 0.48 20.68
1038 0 2540000 0.91 23.21
1039 1 224000 0.18 51.23
1040 1 2260000 0.48 29.01
1041 1 72000 0.27 15.32
1042 0 85000 2.33 16.29
1043 1 3390000 0.50 34.09  
*Unpaired subjects’ raw data from the third clinical study (n=43, unpaired), 
including HLA-DRB1*04 biomarker information (0 = negative; 1 = positive), 
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mutans streptococci counts, unstimulated salivary flow rates, and total IgA 
concentration. Subject 1029 presents no data in the salivary flow column since the 
data was inadvertently not recorded.  
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Table 3. Matched DRB1*04 positive and negative subjects by age, sex within a 
Caucasian population* 
Age Sex Age Sex
5.5 M 6 M
6 M 8 M
7 M 9 M
18 F 19 M
8 M 13 M
32 F 32 F
22 F 27 F
23 F 30 F
31 F 30 F
6 F 9 M
27 M 30 M
7 F 11 F
34 M 34 M
31 M 30 M
36 F 34 F
19 F 26 F
26 F 30 F
21 F 26 F
DRB1*04 Positive DRB1*04 Negative
Matched (Paired) Subjects (n = 32)
 
*Subjects were matched by age before any data analysis was performed. The 
algorithm used simply included matching sex perfectly, if at all possible, then 
matching age as close as possible within this Caucasian population. White 
Hispanics were not excluded, but were not seen.  
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Table 4. Raw ICDAS-II descriptive statistical data* 
Descrip. 
Statistics
# surfaces 
with 
ICDAS ≥ 1
# surfaces 
with 
ICDAS ≥ 3
# filled 
surfaces
# surfaces 
missing 
due to 
caries
Descrip. 
Statistics
# surfaces 
with 
ICDAS ≥ 1
# surfaces 
with 
ICDAS ≥ 3
# filled 
surfaces
# surfaces 
missing 
due to 
caries
Mean 2.39 1.33 11.28 1.61 Mean 0.71 0.49 2.10 0.38
SD 4.38 2.54 8.35 3.96 SD 0.95 0.78 1.13 0.90
SE 1.03 0.60 1.97 0.93 SE 0.22 0.18 0.27 0.21
Mean 3.56 0.96 21.04 1.16 Mean 0.91 0.26 2.75 0.33
SD 6.14 3.45 15.44 2.94 SD 1.05 0.67 0.97 0.78
SE 1.23 0.69 3.09 0.59 SE 0.21 0.13 0.19 0.16
Mean 2.69 1.50 11.56 1.81 Mean 0.79 0.55 2.10 0.43
SD 4.57 2.66 8.57 4.17 SD 0.97 0.81 1.17 0.94
SE 1.14 0.66 2.14 1.04 SE 0.24 0.20 0.29 0.24
Mean 4.25 1.38 18.00 1.44 Mean 1.03 0.32 2.60 0.39
SD 7.01 4.29 12.98 3.39 SD 1.10 0.81 1.02 0.86
SE 1.75 1.07 3.24 0.85 SE 0.28 0.20 0.25 0.21
Log Transformed ICDAS-II Data 
DRB1*04+, Unpaired (n =18)
Negative, Unpaired (n = 25)
DRB1*04+, Paired (n =16)
Negative, Paired (n = 16)
Untransformed ICDAS-II Data
DRB1*04+, Unpaired (n =18)
Negative, Unpaired (n = 25)
DRB1*04+, Paired (n =16)
Negative, Paired (n = 16)
 
*Raw ICDAS-II descriptive statistical data (for both the unpaired, n=43 sample, 
and the paired, n=32 sample), describing the number of lesions fitting the criteria 
of ICDAS-II ≥ 1 or ICDAS-II ≥ 3, or the total number of filled or missing surfaces 
due to prior caries experience. In order to normalize the distribution among 
ICDAS-II scores, these data were transformed by taking the natural log (right 
side of the table).  
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Table 5. Numbers of ICDAS-II lesions in each ICDAS-II category for all subjects* 
# surfaces 
with 
ICDAS=1
# surfaces 
with 
ICDAS=2
# surfaces 
with 
ICDAS=3
# surfaces 
with 
ICDAS=4
# surfaces 
with 
ICDAS=5
# surfaces 
with 
ICDAS=6
DRB1*04 positive-all
Mean 0.17 0.89 0.44 0.61 0.28 0.00
SD 0.38 2.05 1.04 1.69 0.67 0.00
SE 0.36 0.71 0.20 0.32 0.08 0.16
DRB1*04 negative-all
Mean 0.44 2.16 0.24 0.48 0.08 0.16
SD 1.80 3.57 1.01 1.61 0.40 0.80
SE 0.36 0.71 0.20 0.32 0.08 0.16
DRB1*04 positive-match
Mean 0.19 1.00 0.50 0.69 0.31 0.00
SD 0.40 2.16 1.10 1.78 0.70 0.00
SE 0.10 0.54 0.27 0.44 0.18 0.00
DRB1*04 negative-match
Mean 0.69 2.19 0.38 0.63 0.13 0.25
SD 2.24 3.43 1.26 2.00 0.50 1.00
SE 0.56 0.86 0.31 0.50 0.13 0.25
n = 18
n = 25
n = 16
n = 16
Descriptive Statistic 
Labels for DRB1*04 
Positive and Negative
 
*Notice that the mean number of surfaces in the irreversible categories (ICDAS-II 
= 3, 4, and 5) are higher in the DRB1*04 positive group compared to its negative 
counterpart across all samples. The opposite is true with regard to reversible 
lesions (ICDAS-II = 1 or 2). 
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Table 6. Untransformed and transformed ICDAS-II data mimicking DMFS 
measures as well as irreversible to reversible ratios*  
# filled 
surfaces
# surfaces 
missing 
due to 
caries
# surfaces 
with 
ICDAS>=3 
or filled
# filled 
surfaces
# surfaces 
missing 
due to 
caries
# surfaces 
with 
ICDAS>=3 
or filled
ratio: # 
irreversible 
(ICDAS>=3) 
/ # 
reversible 
(ICDAS=1 
or 2)
ratio: # 
irreversible 
(ICDAS>=3 
or filled) / # 
reversible 
(ICDAS=1 
or 2)
ratio: # 
irreversible 
(ICDAS>=3 
or filled or 
missing 
due to 
caries) / # 
reversible 
(ICDAS=1 
or 2)
DRB1*04 positive-all
Mean 10.2 1.6 11.3 1.9 0.4 2.0 0.02 1.54 1.61
SD 8.6 4.0 9.6 1.2 0.9 1.2 0.42 1.20 1.23
SE 2.0 0.9 2.3 0.3 0.2 0.3 0.10 0.28 0.29
DRB1*04 negative-all
Mean 20.3 1.2 21.0 2.6 0.3 2.7 -0.55 1.85 1.90
SD 15.7 2.9 16.2 1.1 0.8 1.1 0.84 1.18 1.15
SE 3.1 0.6 3.2 0.2 0.2 0.2 0.17 0.24 0.23
DRB1*04 positive-match
Mean 11.3 1.8 12.6 2.1 0.4 2.2 0.02 1.65 1.72
SD 8.5 4.2 9.4 1.2 0.9 1.2 0.44 1.21 1.23
SE 2.1 1.0 2.4 0.3 0.2 0.3 0.11 0.30 0.31
DRB1*04 negative-matc
Mean 17.7 1.4 18.8 2.6 0.4 2.6 -0.61 1.71 1.78
SD 12.7 3.4 13.5 1.0 0.9 1.0 0.82 1.10 1.05
SE 3.2 0.8 3.4 0.3 0.2 0.3 0.21 0.28 0.26
Comparison
2-sample t-test - all 0.01 0.69 0.02 0.06 0.84 0.08 0.01 0.40 0.43
2-sample t-test - match 0.11 0.78 0.14 0.20 0.90 0.24 0.01 0.88 0.88
paired t-test - match 0.12 0.80 0.16 0.21 0.91 0.24 0.02 0.88 0.88
ICDAS-II untransformed data ICDAS-II log transformed data Log transformed irreversible ratios
Descriptive Statistic 
Labels for DRB1*04 
Positive and Negative
p-values
n = 18
n = 25
n = 16
n =16
 
*Filled surfaces, missing surfaces due to caries, as well as irreversible lesions are 
accounted for here. Moreover, the ratio of the number of irreversible lesions to 
the number of reversible lesions (# ICDAS>=3 / # ICDAS=1 or 2) has been 
calculated and presented. Furthermore, adding the number of filled surfaces to 
this measure and also the number of missing surfaces provides three separate 
ways to analyze the irreversible to reversible caries ratio. Although the ratio itself 
is statistically significant whether including all recruited subjects (n=43) or within 
the matched group (n=32), by adding the other irreversible measures (filled and 
missing surfaces), this ratio becomes statistically insignificant and the groups 
ultimately appear to be indistinguishable in caries outcomes. Notice that 
although some of the untransformed data is statistically significant when 
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analyzing the entire sample of subjects, these p-values are not valid since the 
distribution of scores is non-normal and therefore these numbers cannot be 
interpreted in any meaningful way. 
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Figure 1. Schematic and diagramatic representations of the surface protein 
adhesin, I/II. I/II comprises the following regions (and residues): the signal 
sequence (1-38), a pre-A region (39-120), the A-region (121-447), V-region (aa 448-
839), P-region (840-983), and the C-terminal region (984-1463), and regions for 
anchor proteins associated with the bacterial cell wall including the the LPxTG 
anchor region (CWA) (1464-1561). The A-region consists of three to four 
(represented here as four) alanine-rich tandem repeats, specifically A1 (121-201), 
A2 (202-283), A3 (284-365), and A4 (366-447). The P-region also consists of three 
to four repeated regions (represented here as four) with about 35 percent proline 
content, including P1 (840-878), P2 (879-917), P3 (918-956), and P4 (957-983) 
(Larson et al., 2010; van Dolleweerd et al., 2004).  
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Figure 2. Human salivary IgA (from pooled samples, n=3) immunoreactivity to 
selected putative epitopes of an S. mutans adhesin, I/II. Reactivity for seven 
selected peptides (803-822, 824-843, 834-853, 925-944, 985-1004, 1085-1104, and 
1095-1114; numbers reflect amino acid residues; 10 µg mL-1) was determined in 
triplicate using ELISA, on low binding ELISA plates, and detected by a horse 
radish peroxidase (HRP)-labeled, anti-human IgA conjugate from goat (1:500 
dilution in TS), and subsequent reaction with o-Phenylenediamine 
dihydrochloride (OPD). These data are reported in optical density absorbance 
(490 nm) as means and standard errors of the mean.   
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Figure 3. Human salivary IgA (from pooled samples, n=3) immunoreactivity to 
selected putative epitopes of an S. mutans adhesin, I/II. Reactivity for seven 
selected peptides (803-822, 824-843, 834-853, 925-944, 985-1004, 1085-1104, and 
1095-1114; numbers reflect amino acid residues; 100 µg mL-1) was determined in 
triplicate using ELISA, on low binding ELISA plates, and detected by a horse 
radish peroxidase (HRP)-labeled, anti-human IgA conjugate from goat (1:500 
dilution in TS), and subsequent reaction with o-Phenylenediamine 
dihydrochloride (OPD). These data are reported in optical density absorbance 
(490 nm) as means and standard errors of the mean.  
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Figure 4. Selected amplification curves for Human HLA-DRB1*04 genotyping. 
Saliva samples were collected and stored in Oragene® DNA sample collection 
kits until DNA purification. DRB1*04 positive subjects (n=8) were determined by 
the presence of a fluorescence signal (exponential amplification curves) from 
HLA-DRB-speciﬁc ﬂuorogenic probes, by polymerase chain reaction (PCR) for 25 
cycles using the LightCycler ® 480 Real-Time PCR System. PCR products were 
analyzed at 465-510 nm. Three gold-standard cell lines were used as positive and 
negative controls, one being homozygous for the biomarker, the other 
heterozygous, and the third negative (see Materials and Methods). Negative 
subjects (n=17) are represented in the horizontal plane. 
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Figure 5. Human salivary IgA immunoreactivity of HLA-DRB1*04 positive (n=8) 
and negative subjects (n=7) to 7 of 10 selected putative epitopes of an S. mutans 
adhesin, I/II. Reactivity (1:10 saliva dilution in TS) to each selected peptide (361-
386, 824-843, 834-853, 925-944, 985-1004, 1085-1104, and 1095-1114; numbers 
reflect amino acid residues; 10 µg mL-1) was determined in triplicate using 
ELISA, on high-binding ELISA plates, and detected by HRP-labeled, anti-human 
IgA (1:500 dilution in TS), and subsequent reaction with OPD. These data are 
reported in optical density absorbance (490 nm) as means and standard errors of 
the mean. 
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Figure 6. Optimization of human salivary IgA (pooled) immunoreactivity to one 
selected putative epitope of an S. mutans adhesin, I/II. Reactivity (1:10 and 1:20 
saliva dilutions in TS) to the selected peptide (1085-1104; numbers reflect amino 
acid residues; 1 µg mL-1) was determined in triplicate using ELISA, on high-
binding ELISA plates, and detected by HRP-labeled, anti-human IgA (at 4 
separate dilutions: 1:5,000, 1:10,000, 1:15,000, and 1:20,000 in TS), and subsequent 
reaction with OPD. These data are reported in optical density absorbance (490 
nm) as means and standard errors of the mean. 
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Figure 7. Optimization of human (unidentified subject #1) salivary IgA 
immunoreactivity to one selected putative epitope of an S. mutans adhesin, I/II. 
Reactivity (1:10 and 1:20 saliva dilutions in TS) to the selected peptide (1085-1104; 
numbers reflect amino acid residues; 1 µg mL-1) was determined in triplicate 
using ELISA, on high-binding ELISA plates, and detected by HRP-labeled, anti-
human IgA (at 4 separate dilutions: 1:5,000, 1:10,000, 1:15,000, and 1:20,000 in TS), 
and subsequent reaction with OPD. These data are reported in optical density 
absorbance (490 nm) as means and standard errors of the mean. 
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Figure 8. Optimization of human (unidentified subject #2) salivary IgA 
immunoreactivity to one selected putative epitope of an S. mutans adhesin, I/II. 
Reactivity (1:10 and 1:20 saliva dilutions in TS) to the selected peptide (1085-1104; 
numbers reflect amino acid residues; 1 µg mL-1) was determined in triplicate 
using ELISA, on high-binding ELISA plates, and detected by HRP-labeled, anti-
human IgA (at 4 separate dilutions: 1:5,000, 1:10,000, 1:15,000, and 1:20,000 in TS), 
and subsequent reaction with OPD. These data are reported in optical density 
absorbance (490 nm) as means and standard errors of the mean. 
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Figure 9. The log transformed number of S. mutans colony forming units mL-1 for 
DRB1*04 positive (n=16) and negative subjects (n=16). Aliquots of whole saliva 
(0.9 mL) were prepared with glycerin (0.2 mL), and were stored at -80°C until 
they were thawed for analysis. Each sample was diluted 1:100 in sterile saline, 
double-plated on Mitis Salivarius agar supplemented with bacitracin and sucrose 
(MSSB) (Anaerobe Systems, Morgan Hill, California). The plates were incubated 
for 48 hours at 37°C, 5 percent CO2, and subsequently the number of S. mutans 
colonies enumerated using Protocol (Synoptic LTD, North Cambridge, UK), thus 
yielding S. mutans colony-forming units/mL (CFU mL-1). These data are reported 
as natural log means and standard errors of the mean. 
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Figure 10. Salivary flow rate in mL min-1 for DRB1*04 positive (n=18) and 
negative subjects (n=25). Flow rate was calculated by taking the amount of saliva 
provided by each subject and dividing by the number of minutes it took them to 
yield that amount. These data are reported as means and standard errors of the 
mean. 
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Figure 11. Human salivary IgA immunoreactivity of HLA-DRB1*04 positive 
(n=16) and negative subjects (n=16) to 10 selected putative epitopes of an S. 
mutans adhesin, I/II. Reactivity (1:10 saliva dilution in TS) to each selected 
peptide (361-386, 803-822, 824-843, 834-853, 925-944, 985-1004, 1005-1025, 1025-
1044, 1085-1104, and 1095-1114; numbers reflect amino acid residues; 1 µg mL-1) 
was determined in triplicate using ELISA, on high-binding ELISA plates, and 
detected by HRP-labeled, anti-human IgA (1:10,000 dilution in TS), and 
subsequent reaction with OPD. These data are reported in optical density 
absorbance (490 nm) as means and standard errors of the mean. 
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Figure 12. Standard curve fit to data points from standard concentrations of 
human colostral IgA, including 200, 100, 50, 25, 12.5, 3.1, and 0 µg mL-1, 
respectively. Absorbance values are used to predict actual concentrations of total 
salivary IgA. Calculations were performed by using the standard curve equation 
from a log-log function (R2 = 0.991), and then plugging each subject’s reactivity 
(1:15 saliva dilution in TS) to unlabeled, human IgA into the function providing 
the correct concentration in µg mL-1. The total salivary IgA concentrations in all 
43 subjects ranged from 11.1-420.4 µg mL-1, in agreement with recent data that 
demonstrated total salivary IgA concentrations range from 13.7-483.0 µg mL-1 in 
134 healthy individuals (Booth et al., 2009).   
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Figure 13. Human salivary total IgA among HLA-DRB1*04 positive (n=18) and 
negative subjects (n=25). Calculations were performed by creating a standard 
curve (see Fig. 12) by fitting data based on colostral IgA standard concentrations 
in a log-log function (R2 = 0.991), and then plugging each subject’s reactivity (1:15 
saliva dilution in TS) to unlabeled, human IgA into the log-log function 
providing the value as illustrated in this figure. Reactivity was determined in 
triplicate using ELISA, on high-binding ELISA plates, and detected by HRP-
labeled, anti-human IgA (1:10,000 dilution in TS), and subsequent reaction with 
OPD. These data are reported as means and standard errors of the mean. 
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Figure 14. Human salivary IgA specific activity of HLA-DRB1*04 positive (n=16) 
and negative subjects (n=16) to 10 selected putative epitopes of an S. mutans 
adhesin, I/II. Specific activity was calculated using the natural log of the ratio of 
each subject’s SIgA OD reading for each epitope to the total IgA OD for each 
subject. Reactivity (1:10 saliva dilution in TS) to each selected peptide was 
determined in triplicate using ELISA, on high-binding ELISA plates, and 
detected by HRP-labeled, anti-human IgA (1:10,000 dilution in TS), and 
subsequent reaction with OPD. These data are reported in natural log values as 
means and standard errors of the mean.  
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Figure 15. Human salivary IgA immunoreactivity of HLA-DRB1*04 positive 
(n=16) and negative subjects (n=16) to whole cells of S. mutans (UA159, NG8, and 
NG8-derived I/II-deficient, PC3370). Each strain was initially diluted in sodium 
carbonate/bicarbonate buffer until a 0.5 OD was achieved at 660 nm. Reactivity 
(1:4 saliva dilution in TS) to each strain was determined in triplicate using ELISA, 
on high-binding ELISA plates, and detected by HRP-labeled, anti-human IgA 
(1:10,000 dilution in TS), and subsequent reaction with OPD. These data are 
reported in optical density absorbance (490 nm) as means and standard errors of 
the mean. 
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Figure 16. Human salivary IgA reactivity ratios of HLA-DRB1*04 positive (n=16) 
and negative subjects (n=16) to 10 selected putative epitopes of an S. mutans 
adhesin, I/II / whole cell S. mutans UA159 (UA159). Reactivity (1:10 saliva 
dilution in TS) to each selected peptide or to UA159 was determined in triplicate 
using ELISA, on high-binding ELISA plates, and detected by HRP-labeled, anti-
human IgA (1:10,000 dilution in TS), and subsequent reaction with OPD. These 
data are reported in natural log values as means and standard errors of the mean.  
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Figure 17. Human salivary IgA specific activity of HLA-DRB1*04 positive (n=18) 
and negative subjects (n=25) to three strains of whole cells of S. mutans (UA159, 
NG8, and NG8-derived I/II-deficient, PC3370). Specific activity was calculated 
using the natural log of the ratio of each subject’s SIgA OD reading for each 
strain to the total IgA OD for each subject. Reactivity (1:10 saliva dilution in TS) 
to each strain was determined in triplicate using ELISA, on high-binding ELISA 
plates, and detected by HRP-labeled, anti-human IgA (1:10,000 dilution in TS), 
and subsequent reaction with OPD. These data are reported in natural log values 
of optical density absorbance (490 nm) as means and standard errors of the 
mean. 
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Figure 18. Human salivary IgA immunoreactivity to the entire I/II antigen on 
NG8 (indirect measure) in HLA-DRB1*04 positive (n=18) and negative (n=25) 
subjects. Reactivity (1:10 saliva dilution in TS) to NG8 and a I/II-deficient strain 
(PC3370) was determined in triplicate using ELISA, on high-binding ELISA 
plates, and detected by HRP-labeled, anti-human IgA (1:10,000 dilution in TS), 
and subsequent reaction with OPD. These data were calculated by subtracting 
OD 490 nm PC3370 values from NG8 values. Biologically, this means that in a 
simplified model the components of PC3370 (i.e., GTFs, and GBPs) are subtracted 
from all the components of NG8 (i.e., I/II, GTFs, and GBPs), thereby leaving only 
I/II to examine. These data are reported in optical density absorbance (490 nm) as 
means and standard errors of the mean. 
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Figure 19. The HLA-DRB1*04 positive subjects (n=16) exhibit numerically, but 
not statistically significant, increased numbers of irreversible ICDAS-II scores 
compared to a negative group (n=16; see Materials and Methods for criteria 
details). Raw scores were natural log transformed. These data are reported in 
natural log values as means and standard errors of the mean. 
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CHAPTER FIVE 
Discussion 
Previous literature, as reviewed in chapter one, has suggested that HLA-
DRB1*04 appears to be a caries susceptibility allele in Caucasian populations. 
These results do not disprove this notion, but argue for a more nuanced and 
complicated landscape regarding the immunogenetics of caries. Given the 
sample size in both of the current clinical studies (n=15) and (n=43, unpaired; 
n=32, paired), it was not anticipated to uncover any statistically significant results 
at the clinical level although trends were expected. Rather, power analyses were 
based on the primary outcome of SIgA reactivity to selected epitopes, which had 
not previously been studied in this context.  
Clinically, the results confirmed that the sample size was too low for any 
major statistically significant clinical finding, however an emergent trend was 
also absent. Nonetheless, compared to their non-biomarker counterparts (n=25, 
unpaired; n=16, paired) DRB1*04 positive subjects (n=18, unpaired; n=16, paired) 
exhibited a statistically significant difference (p < 0.01, unpaired; p < 0.01, paired) 
with regard to the ratio of the number of irreversible lesions to the number of 
reversible lesions (# ICDAS>=3 / # ICDAS=1 or 2), where higher ratio values may 
suggest a greater progression of the irreversible caries process (table 6). 
Nonetheless, when adding other past caries experience measures to these ratios, 
the groups became indistinguishable from each other (table 6).  
This is an interesting finding since DRB1*04 positive subjects exhibit a 
trend toward lower TIgA and lower S. mutans counts, both of which would lend 
themselves to an increase in the caries process. Instead, the DRB1*04 positive 
subjects in this study seemed to compensate (at least by staying even with their 
negative counterparts in terms of the number of lesions reported) somehow in 
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the face of these putative deficiencies, at least with regard to past experience—in 
comparison to their negative counterparts.  
It is important at this juncture to briefly mention ICDAS-II, a novel 
approach to detect and assess caries. This system for detecting and assessing 
caries was developed by an ad hoc international committee that sought to create 
a unified visual system, with histological support, that researchers and 
practitioners alike could use, where data could be compared no matter the locale 
or point in time. The goal is that data will not only be comparable but also 
compatible and more easily shared the world over. The ICDAS-II “system is 
practical [and] has content validity, correlational validity, [as well as] 
discriminatory validity” (Ismail et al., 2007). Its reliability “has been found to be 
in the range of good to excellent (kappa coefficients range between 0.59 and 
0.82).” Furthermore, researchers have demonstrated that the ICDAS-II non-
cavitated “diagnostic threshold specificity was 0.74–0.91 and sensitivity was 
0.59–0.73” (Jablonski-Momeni et al., 2008). The “ICDAS-II system demonstrates 
reproducibility and diagnostic accuracy for the detection of occlusal caries at 
varying stages of the disease process,” and provides the added bonus of high 
validity and reliability compared to other caries measures. Disadvantages of this 
system involve its activity scale as it is not well validated. Additionally, 
interproximal lesions cannot be visualized. Nonetheless, it is as good or better 
than any other comprehensive caries lesion measurement criteria (Rodrigues et 
al., 2008). 
With regard to I/II epitopes, the results shown here do not fully align with 
the hypothesis but are not inexplicable. In every case, except for one, DRB1*04 
positive subjects exhibit a weak trend toward higher SIgA reactivity than their 
non-biomarker counterparts. At the SIgA level, this is contrary to the hypothesis, 
but appears to be the case though none of these data reach statistical significance. 
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Nonetheless, it is certainly possible that DRB1*04 positive subjects could 
nonetheless exhibit an increase in the irreversible stages of the caries process 
since there are many more epitopes of I/II than what was measured, and there 
are more adhesins involved in cariogenic colonization of S. mutans than simply 
I/II. It may be that the epitopes involved in this study have little to do with I/II 
attachment and virulence, or are only components of immunogenic 
discontinuous epitopes that must function together. In fact, data suggest that 
DRB1*04 positive subjects exhibit a lower SIgA response to I/II of S. mutans NG8 
compared to their non-biomarker counterparts (Fig. 18). This further suggests 
that I/II is still important but that the selected epitopes do not tell the whole 
story. Moreover, both GTFs and GBPs are also important. Researchers have 
hypothesized that HLA-II alleles produce the differences in immunological 
responses observed to GbpB immunogenic epitopes (Nogueira et al., 2005). 
Nevertheless, the previous results demonstrate that DRB1*04 positive subjects 
are slightly higher responders to a I/II-deficient strain (PC3370) of S. mutans, as 
well as to the I/II replete NG8 and UA159 strains (Figs. 15 & 17), meaning that 
these subjects are immunologically competent to GBPs and other adhesins, 
compared to these negative counterparts. Additionally, by subtracting the I/II-
deficient strain’s reactivity from NG8’s activity, an elegant indirect measure of 
reactivity to the entire I/II antigen is created, demonstrating that I/II is where 
DRB1*04 positive subjects may exhibit a lower immune response (Fig. 18). This is 
in agreement with a previous study where two DRB1*04 allelic variants 
demonstrated lower reactivity to SIgA than their negative counterparts to the 
entire I/II antigen (Wallengren et al., 2005). Unfortunately, a purified sample of 
the entire sequence of I/II was not available. This measure is especially helpful 
since I/II in its entirety is notoriously unstable and degrades rapidly in vitro; thus 
it it very difficult to study in isolation as a whole.      
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Continuing this theme, it is interesting to note that of all 10 epitopes 
assayed, one epitope (834-853; which straddles the carboxy-terminus of the V 
region and encompasses most of the P1 region) demonstrated the opposite trend 
across all measures (Figs. 11, 14, 16), a trend that nicely illustrates the original 
hypothesis. More interesting is that this epitope, along with one other (1085-1104; 
in the C-terminal domain), was originally identified in the first laboratory study, 
using pooled saliva, as being most important after normalizing those data (data 
not shown). These results regarding 834-853 support the initial hypothesis. 
Taking into account those data demonstrating lower reactivity to the entire I/II 
antigen, the evidence suggests that 834-853 may be one part of a discontinuous 
epitope involved in attachment to the acquired salivary pellicle on the tooth 
surface. There is new data which suggests that this may be the case.  
Although the A and P regions have been known to be important as 
regions that interact and serve as docking sites for discontinuous epitopes, the 
variable region is now known to also be very important (Larson et al., 2010). 
Researchers have suggested that I/II presents a lectin-like (i.e., carbohydrate-
binding) domain in the middle of the V region important in bacterial adhesion 
(Troffer-Charlier et al., 2002); for example, in binding fibronectin (Jakubovics et 
al., 2009) or “collagen, laminin, keratin, fibrinogen and other oral 
microorganisms”  (McArthur et al., 2007). It is very interesting to note that 834-
853 encompasses the very residues (interacting with 464-471, which were not 
examined in these studies) that make up the distal arm of the V region (the 
reactive part of the arm, which is made up of proximal and distal regions) of 
what has recently been called a hinge-like area of I/II, which interfaces with all 
three major regions (A, V, and P) of I/II and supports the flexure of what is now 
known to make up most of the length of I/II, the stalk (Larson et al., 2010). Not 
only does the distal arm provide flexing in unison by the A, V, and P regions, but 
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it is also involved in governing intermolecular interactions among the backbone 
of I/II such as solidifying the proximal arm’s hydrophobicity, which is locked 
interiorly by hydrogen bonding and salt-bridges (Troffer-Charlier et al., 2002). 
The backbone of the V region is very important and features an unmistakable 
crevice, which is a calcium-dependent preformed binding site whose every 
feature suggests it is a carbohydrate-binding cleft that undergoes little 
conformational change in the face of ligand binding. Water and calcium appear 
to also function as “direct sugar ligands.” Even more, the V region exhibits 
sequence homology with S. mutans GbpC, which of course can bind glucan that 
is synthesized by GTFs and aid the development of the biofilm. Nevertheless, it 
is clear that the V region does not act alone but rather functions in tandem via its 
distal arm (serving as a sort of center for functionality) with its sister domains.         
In fact, it is the three-dimensional interaction of the A, V, and P regions 
that predominantly affects S. mutans attachment to a dental pellicle protein, 
gp340, alternatively called salivary agglutinin (SAG) or DMBT1 (deleted in 
malignant brain tumors 1). Human gp340 belongs to a family of innate immune 
proteins that are characterized by scavenger receptor cysteine-rich (SRCR) 
proteins. There are SRCR domains along the entire length of gp340, which serve 
as the binding sites for the specific arrangement of particular sections of the A, V, 
and P regions within I/II. When in the planktonic form, SRCRs provide gp340 the 
ability to serve as a pattern recognition receptor (Loimaranta et al., 2009). Thus, 
gp340 “promotes bacterial aggregation and clearance” (Nobbs et al., 2009) when 
it encounters S. mutans planktonically. However, when the glycoprotein is 
embedded in the tooth pellicle or on the epithelium or on microbes themselves 
(i.e., immobilized in dental biofilm), it instead serves as a receptor for 
streptococcal attachment (Jakubovics et al., 2005). 
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S. mutans I/II was recently demonstrated to be a singular protein, very 
different from what has been heretofore understood about other proteins in 
nature. Until 2 months ago, a hybrid structure of α-helices and polyproline type 
II (PPII) helices intimately associated with each other was unknown (Larson et 
al., 2010). Nonetheless, this is the case for I/II. Proline-rich areas are ubiquitous in 
functionally important proteins throughout nature (Jin et al., 2009).  Many 
proline-rich regions, such as the P region within I/II, exhibit repeated motifs, 
which form “left-handed polyproline II helical conformations (PPII).” PPII 
helices are more flexible than other regular structures such as α-helices or β-
sheets, but are nonetheless solid due to the “rigidity of the proline ring,” echoing 
what was previously said about the functionality of the distal arm of the V 
region, which is also linked and a part of the amino terminus of the P region, 
whose existence provides a hinge-region allowing the I/II stalk to flex as a unit 
and yet maintain a V region hydrophobic core that is locked in place.  
Larson et al. recently reported the entirely unique (the first of its kind) α-
helical structure intimately conjoined with PPII helices:      
Here we report a high-resolution (1.8 Å) crystal structure of the 
A3VP1 fragment of S. mutans AgI/II that demonstrates a unique 
fibrillar structure (155 Å) formed by the intimate association of two 
widely separated segments within the primary sequence. The A3 
repeat of the alanine-rich domain was found to adopt a long α-
helical structure that intertwines with the P1 repeat polyproline 
type II (PPII) helix to form a highly extended stalk. . . . [There is] a 
high-affinity interaction between the α- and PPII helices. . . . 
together the three A/P repeat units account for the majority of the 
length of AgI/II. [We] identified two distinct binding sites on AgI/II 
for it’s host receptor [gp340]. Finally, we propose a model for 
AgI/II’s interaction with [gp340]. . . . It is now apparent that AgI/II 
is a highly extended fibrillar structure formed by a long and 
continuous A–P association. This architecture would position the 
globular V region at the tip of the stalk away from the cell surface, 
 102 
 
with the C-terminal region positioned near the cell surface and the 
pre-A region in close proximity (Larson et al., 2010). 
 
What insight does this new found structure provide? For one, it 
demonstrates that A3 and P1 (and V) interactions, of which 834-853 is crucially 
involved and center stage, serve as a primary gp340 binding domain. It also 
demonstrates that a secondary gp340 binding site is located in the C-terminal 
domain, meaning that after the globular V region (coupled with the amino 
terminus of the P region and the carboxy terminus of the A region) initially 
adheres to the salivary pellicle, the distal arm can flex to such a degree that the 
C-terminal domain, which abuts the anchor motif on S. mutans itself, can actually 
bind gp340 as well. Thus, if host SIgA sufficiently responds to this very 
particular region, I/II will not be able to take advantage of these binding sites and 
the process of caries will be abated or slowed. Alternatively, if there were low 
SIgA responses to this particular epitope located in the distal arm region, it 
would follow that I/II could take full advantage of its array of virulent 
mechanisms, which fits the hypothesis with regard to the DRB1*04 positive 
group and the epitope found at 834-853. That the negative group may exhibit a 
better ability to naturally fight the disease while still in the reversible stage is 
supported by the fact of higher reactivity to NG8 and a higher 834-853 epitope 
response.  
Active oral immunization with antigen I/II in rats produces an increase in 
specific SIgA antibody and a concomitant decrease in S. mutans thus protecting 
against caries (no statistical difference in S. mutans was seen in the paired study), 
while systemic active immunization in monkeys induces specific serum IgG 
antibodies that also inhibit S. mutans colonization and inhibit the development of 
caries by expressing themselves on the tooth via the gingival crevicular fluid 
(Lehner et al., 1989; Ma et al., 1990). One reason why inducing these antibodies 
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inhibits caries is that SIgA antibody apparently binds at critical points along I/II, 
probably especially in the distal arm region, thus depriving S. mutans of its main 
adhesin, which normally facilitates attachment to the tooth surface. Since the 
goal of any type of immunization against caries is blocking bacterial adhesion, 
and thus preventing lesion formation (Fontana et al., 2000), pursuing this path is 
one way forward. Active immunization in these animal models clearly shows 
protection against caries.  
But local passive immunization has been touted as less immunogenic and 
avoids the untoward consequences of a systemic immune response. One study 
showed that of two groups of rhesus monkeys exposed to a human-type diet, 
none that were immunized with IgG (i.e., the experimental group) developed 
caries over a one-year period (Lehner et al., 1985). Those who were not 
immunized (i.e., the control group), not only developed caries, but did so 
irrespective of whether the surface was smooth or fissured. The working 
hypothesis of how this happens is that antibodies interact with specific epitopes 
of I/II, perhaps the distal arm of the V region, priming S. mutans to become 
opsonized, phagocytosed, and destroyed by gingival neutrophils. An article in 
Nature Medicine used this approach in humans but synthesized SIgA antibodies 
from plant-derived material, which theoretically rendered the foreign antibodies 
even safer and more serologically compatible (Ma et al., 1998). In this work, four 
months after passive immunization with the plant antibodies the foreign salivary 
IgA significantly decreased microbial colonization.  
Ultimately, however, how antibodies relate to their HLA gene encoding 
counterparts remains to be explored. As these fundamental mechanisms become 
better understood in the long-term, our ability to design vaccines will not only 
increase but also enable us to individually tailor immunizations. 
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What this means at the host level is that the DRB1*04 positive group may 
have some sort of decreased immune response with regard to clearing the 
infection by mounting an appropriate immune response, whereas the negative 
group is more immunocompetent. These findings diverge in some respects with 
previous findings, two of which are here mentioned, where a serologically 
determined DR4 positive group was related to high DMFS scores and a negative 
group was not (Lehner et al., 1981), and DRB1*04 positive subjects younger than 
5 years of age were 10 times more likely to develop early childhood caries (ECC; 
defined as “one or more decayed (noncavitated or cavitated), missing (due to 
caries), or filled tooth surfaces in any primary tooth in a child 71 months of age 
or younger.”) than their negative counterparts (Bagherian et al., 2008).    
These studies have been interesting, but there is much more to uncover 
with regard to the biological aspects of caries. One could imagine that the genetic 
portion of this disease is something like 30 percent or higher, and that the 
environmental component is something like 70 percent. Yet, until recently little 
was known regarding the proportion of the caries disease process that is 
specifically affected by genetics, or what proportion environment contributes to 
the disease. In robust samples in twin populations, recent studies have 
demonstrated upwards of 50 percent of caries variability is explained by genetic 
factors (Bretz et al., 2005). Family studies, in contrast to twin studies, are better 
predictors of genetic contributions since they greatly minimize non-genetic 
confounding contributions to the disease. Very recently, the largest (n=2,600; 740 
families), most well-designed caries heritability study ever completed was 
published (Wang et al., 2010). The authors found that “caries phenotypes in the 
primary dentition were highly heritable, with genes accounting for 54–70% of 
variation in caries scores. The heritability of caries scores in the permanent 
dentition was also substantial (35–55%, all p < 0.01).” It is important know why 
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exactly family studies are better at eliminating confounding environmental 
variables compared to twin studies. In the words of the authors: 
[The] strength of our family study design is that, compared to twin 
studies, it is less susceptible to inflated heritability estimates caused 
by non-genetic familial factors. This is because twins (including 
dizygotic twins) are likely to share unmeasured environmental and 
behavior exposures that track with kinship coefficient (degree of 
relatedness), whereas inclusion of more distant relatives, such as 
half-siblings raised separately, cousins, and parent-offspring pairs 
(reared at different times and in different environments), help 
insulate heritability estimates from the effects of familial non-
genetic exposures.  
 
This article demonstrated that in children genetic factors may account for 
upwards of 70 percent of the variation in caries scores, while in adults the 
contribution decreases to as low as 35 percent (but as high as 55 percent).  
Nonetheless, it has long been known that caries is also affected in large 
part by exogenous variables, such as oral hygiene, diet, and fluoride exposure, as 
well as psycho-social factors, all of which may change over time in different 
ways. For example, a child’s level of oral hygiene is more dependent on parents 
than the child, but could change dramatically as the child becomes older and 
cognizant of why it is important to brush. An example of how diet could change 
could be a college student who never has time or money to prepare nutrient 
dense foods that his or her parents prepared up until college began. Moreover, if 
this student had genes leading to an increased sucrose sweetness preference 
(Bretz et al., 2006; Fushan et al., 2009), then 4 years in college could completely 
alter caries experience. Fluoride exposure could change if someone moved from 
a fluoridated area to an area whose water supply was unfluoridated. Finally, 
depression and anxiety are two psychological factors that may lead people to 
value oral health much less leading to deleterious oral health outcomes. On the 
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other hand, cultural or social norms could lead some to become obsessive about 
oral health or others to disbelieve the education they receive from oral health 
care professionals. Interestingly, in children, sex and age explain very little of the 
variation in caries experience, yet a significant proportion in adults (Wang et al., 
2010). The fact that many of these factors were not captured is a limitation to the 
studies thus presented. Moreover, these studies are not longitudinal. Much effort 
has gone into seeking to minimize, homogenize, and standardize these 
exogenous factors, primarily by carrying out a matched study where age, sex, 
and a Caucasian population were matched. In an ideal world, all factors could be 
accounted for. Then one could determine to a much better extent the role of both 
environment and genetics.    
Conclusion 
 This research demonstrates both the biological and environmental 
complexity involved in caries. Taken alongside a growing body of literature 
regarding HLA alleles and caries, and its fundamental biological factors, it does 
not discount the notion that DRB1*04 is a biomarker that is involved in a lower 
mucosal immune response against particular discontinuous conformationally 
specific immunogenic epitopes that remain elusive. Although the tested epitopes 
reacted with SIgA to varying degrees, most did not appear to have a large impact 
in the caries process and may be relatively inconsequential with the significant 
exception of epitope 834-853. This epitope located in the distal arm of the V 
region (also connected to the P1 region) is probably very important, and provides 
a biologically sound connection between a lack of SIgA reactivity to its binding 
site, and therefore greater adherence to the tooth structure. All of this said, it is 
important to understand the limitations of this research in that we were unable 
to control for an array of environmental variables that can certainly affect things 
such as bacterial counts, and especially caries outcome data. Nevertheless, we 
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did design a paired study in order to minimize certain environmental factors that 
certainly affect the caries process. 
Future Directions 
Complex immunogenetic pathways involved in the caries disease process 
itself are not only crucial to understanding the fundamental nature of this 
infectious disease, but also essential in paving the way for new algorithms of 
diagnosis and detection (e.g., using biomarkers in lab-on-a-chip technologies to 
distinguish caries-susceptible and caries-resistant patients), vital for developing 
new therapeutic approaches (e.g., vaccines), and crucial in revealing common 
susceptibility alleles. Although HLA-II pathways account for only one piece of 
the caries genomic puzzle, they may prove even more important than suggested 
in this research. Although one HLA binding motif has been revealed within I/II, 
the newly revealed fibrillar structure of I/II “now provides a framework to 
design future studies and to re-examine historical data” (Brady et al., 2010).  
Moreover, according to these authors, “one of the most promising 
strategies seems to be delivery of peptides, derived from glucan-binding protein 
B (GbpB) and antigen I/II (AgI/II) protein, via a mucosal (nasal) route.” Another 
delivery method would involve something as commonplace as toothpaste 
especially to provide much more marketplace penetrance in underdeveloped 
countries. All of this will nonetheless require a definitive assessment of “the 
contribution of antibodies against complex discontinuous epitopes to caries 
protection, in either naturally-sensitized humans or in immunized animals” since 
this has yet to be done. In summary, Brady and colleagues are optimistic about 
the future: 
There is new potential for predicting and generating 
conformational epitopes eliciting protective antibodies. However, 
specificity of function in different Streptococcus species or strains is 
a major issue requiring more detailed and accurate analyses. This 
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may provide key information in understanding site-specificity of 
host colonization by different streptococci. In addition, this 
information is necessary if blocking of AgI/II-like protein functions 
with antibodies, mimetics or via small molecule inhibitors is to be 
developed as a therapeutic route. 
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Orientation, Indiana University and Purdue University at Indianapolis, 
University Library, 1126, USA. [Oral presentation] 
16. Dental Caries: Genetics, Immunology, & Microbiology, February 2009. 
Presented at Oral Examination for PhD Qualifying Exam, Indiana 
University, School of Dentistry, Indianapolis, Indiana, USA. [Oral 
presentation]  
17. Research in Dental Medicine: Biological Connections, April 21, 2009. 
Presented at IUPUI Biology Club, Science Building, Indiana University 
and Purdue University, Indianapolis, Indiana, USA. [Oral Presentation] 
18. 17th Annual Research Day, Indiana University School of Dentistry, 2009. 
Critical Antigen I/II Epitopes of Streptococcus mutans (an additional 
epitope highlighted from previous poster with same title). IUPUI Campus 
Center Room 409, Indianapolis, Indiana, USA, April 23–24, 2009. [Poster 
presentation] 
19. Genetics, Human Leukocyte Antigen Complex Genes & Caries, November 
10, 2009. Presented at the Graduate Student Research Seminar, Indiana 
University, School of Dentistry, Indianapolis, Indiana, USA. [Oral 
presentation] 
20. Why Academic Dentistry? Thoughts on the Journey and Ethics in 
Dentistry, November 19, 2009. Presented at a Graduate Education Seminar 
for 1st year dental students. Indiana University, School of Dentistry, 
Indianapolis, Indiana, USA [Oral presentation] 
21. Human Leukocyte Antigen Complex Genes & The Caries Process, 
December 4, 2009. Presented at the Indiana Association chapter of the 
  
 
American Association of Dental Research, Indiana University, School of 
Dentistry, Indianapolis, Indiana, USA. [Oral presentation] 
22. Antigen Processing & Presentation, March 11, 2010. Presented to 
Advanced Graduates in G959 Graduate Oral Microbiology. Indiana 
University, School of Dentistry, Indianapolis, Indiana, USA [Oral 
presentation]. 
23. 18th Annual Research Day, Indiana University School of Dentistry. 
Genetically Distinct Oral Immunity to Pathogenic Adhesin Epitopes. 
IUPUI Campus Center Room 409, Indianapolis, Indiana, USA, April 12, 
2010. [Poster presentation]. 
24. Annual Meeting of the Indiana Clinical and Translational Sciences 
Institute (CTSI) 2010. Distinct Oral Immunity to Pathogenic Adhesin 
Epitopes. Indiana University, School of Medicine, Health Information and 
Translational Sciences (HITS) Building, Collaboration Area, April 19, 2010. 
[Poster presentation] 
25. Annual National Meeting of Clinical and Translational Science Fellows 
2010. Oral Immunity to Pathogenic Adhesin Epitopes. St. Louis, May 2-4, 
2010. [Poster presentation] 
26. Meeting of Second Year Indiana Clinical and Translational Science 
Fellows. The Immunogenetics of Dental Caries. Regenstrief Institute, 6th 
Floor Boardroom. May 6, 2010 [oral presentation]. 
27. Defense Seminar: The Immunogenetics of Dental Caries. Indiana 
University School of Dentistry, Indianapolis, Indiana, USA. June 4, 2010 
[oral presentation].    
 
PROFESSIONAL MEMBERSHIPS 
American Academy of the History of Dentistry  
American Association for the Advancement of Science 
American/International Association for Dental Research 
American Dental Association 
American Dental Education Association 
Fédération Dentaire Internationale (FDI) World Dental Federation 
Society for Clinical and Translational Science 
 
 
 
 
 
 
 
